2021
E N V I R O N M E N TA L ,SOCIAL &GOVERNANCE REPORTIntroduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

INTRODUCTIONTABLE OF CONTENTS
Introduction......2

About This Report .  .  .  .  .  .  .  .  . 2About Amgen .  .  .  .  .  .  .  .  .  .  .  .  . 3Awards and Rankings .  .  .  .  .  . 5Leadership Message .  .  .  .  .  .  . 6Our Approach to ESG .  .  .  .  .  . 7

COVID-19 Response. . . . .10

COVID-19 Response .  .  .  .  .  . 11

Healthy People. . . . .14

Access to Medicines .  .  .  .  .  . 16
Health Equity . .  .  .  .  .  .  .  .  .  .  .  . 20

Healthy Planet

Environmental
Sustainability . .  .  .  .  .  .  .  .  .  .  .  .  .  . 46

A Healthy Amgen. . . . .25

Diversity, Inclusion andBelonging .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 27
Human CapitalManagement .  .  .  .  .  .  .  .  .  .  .  .  . 33
Community Investment.  .  . 37
Responsible Sourcing . .  .  .  . 42

. . . . . . 53

Corporate Governance.  .  .  .  .  . 55
Business Ethics .  .  .  .  .  .  .  .  .  .  .  .  . 56
Ethical Research .  .  .  .  .  .  .  .  .  .  .  . 58
Patient Safety and ProductQuality .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 60
Cybersecurity andData Privacy .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 63
Government Affairs
and Public Policy. .  .  .  .  .  .  .  .  .  .  . 65

Appendix
Healthy Society. . . . . . 44

. . . . . . 66

UN Global Communications
on Progress.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 66
Company Performance
Data.  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 67
SASB Index .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 68
Forward-Looking
Statements .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 74

ABOUT THIS REPORTThis report describes our progress from January
1, 2021 to December 31, 2021. The content
is informed by our ongoing monitoring ofinternal and external stakeholder perspectives,
direct interactions with stakeholders, a review
of relevant reporting standards and frameworks,
and internal analyses of the alignment ofenvironmental, social and governance (ESG)
topics with our strategy, mission and values.
All of our worldwide business operations areincluded in this report unless otherwise stated.
Throughout this report, we also guide readers
to additional sources of information online.
We have prepared this report in alignment with
the Biopharma Investor ESG Communications
Guidance (the “Guidance”). Launched in 2020,
the Guidance identifies high-priority ESG

2 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

topics for the biopharmaceutical sector andrecommends how to structure information anddisclosures in a useful format for investors. The
Guidance integrates components and principlesof the Sustainability Accounting Standards
Board (SASB) Biotechnology & Pharmaceuticals
Sustainability Accounting Standard, as well as
the Task Force on Climate-Related Financial
Disclosures (TCFD) reporting standard. Our
reporting also reflects our alignment with
the United Nations (UN) Global Compact andSustainable Development Goals.

COVER IMAGES: (Right) Senior Associate Scientist Asha Kelleyin the discovery research lab, Thousand Oaks, California.
(Far left) Induced Proximity Platform: the small molecule shownas green and blue balls (carbons and nitrogens) brings together acomplex of four proteins (red, orange, beige and teal) that doesn’t
exist in nature. This results in the enzymatic destruction of theteal protein, which is a cancer-driving protein.

We value and welcome
feedback from all
stakeholders. Please
send comments orquestions about thisreport to
ESG@AMGEN.COM

Reference to our website is notintended to function as a
hyperlink, and the information
contained on our website is notintended to be part of this report.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

ABOUT AMGEN
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing,and delivering innovative human therapeutics. This approach begins by using tools such as advanced human genetics to unravel the complexities
of disease and understand the fundamentals of human biology.

OUR BELIEF —and the core of our strategy—
is that innovative, highly
differentiated medicines thatprovide large clinical benefits inaddressing serious diseases are
medicines that will not only help
patients, but also help reduce thesocial and economic burdenof disease on society today.

3 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

Amgen focuses on areas of high unmet medical need
and leverages its expertise to strive for solutions that
improve health outcomes and dramatically improve
people’s lives. A biotechnology pioneer since 1980, Amgenhas grown to be one of the world’s leading independent
biotechnology companies, has reached millions of patientsaround the world with its medicines, and is developing apipeline of innovative medicines.
We focus our research in three therapeutic areas:
inflammation, oncology, and general medicine.
Our medicines typically address diseases for which there
are limited treatment options or provide a viable alternative
to those treatments that are otherwise available. Amgen isalso a leader in developing and manufacturing biosimilars(medications that are biologically similar to existing biologic
treatments), which have the potential to offer more affordable,
life-altering treatment options.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

OUR VALUES
Be science-based. Our success depends on superiorscientific innovation, integrity, and continuous improvement
in all aspects of our business through the application of thescientific method. The scientific method is a multistep processthat includes designing the right experiment, collecting
and analyzing data, and rational decision-making. It is not
subjective or emotional, but rather a logical, open, reasoned
process. Applying the scientific method in all parts of theorganization is expected and highly valued.
Compete intensely and win. We compete against time,
past performance, and industry rivals to rapidly achieve
high-quality results. We cannot be lulled into complacency
by previous achievements. Though we compete intensely,
we maintain high ethical standards and demand integrityin our dealings with competitors, customers, partners, andeach other.
Create value for patients, employees, and stockholders.
We provide value by focusing on the needs of patients. Amgencreates a work environment that provides opportunities for
employees to reach their full potential. We strive to provide
stockholders with superior long-term returns while balancing
the needs of patients, employees, and stockholders.
Be ethical. We are relentless in applying the highest ethicalstandards to our products, services, and communications.
Trust and respect each other. Every job at Amgen isimportant, and every Amgen employee is important. We
attract diverse, capable, and committed people and provide
4 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

an environment that fosters inclusion, respect, individual
responsibility, and values diversity. Trust is strengthened
through personal initiative and by obtaining quality
results rapidly.
Ensure quality. Quality is a cornerstone of all of our activities.
We seek the highest-quality information, decisions, andpeople. We produce high-quality products and services.
Quality is woven into the fabric of everything we do. Our
website contains additional information about our approachto Quality and Patient Safety.
Work in teams. Our teams work quickly to move scientificbreakthroughs from the lab through the clinic to themarketplace and to support other aspects of our business.
We believe that diverse teams working together generate
the best decisions for patients, employees, and stockholders.
Our team structure provides opportunities for Amgen
employees to affect the direction of the organization, togain broader perspective about other functions within
Amgen, and to reach their full potential.
Collaborate, communicate, and be accountable.
Leaders at Amgen seek input and involve key stakeholders
in important decisions. In gathering input, strong leaders
will welcome diverse opinions, conflicting views, andopen dialogue for serious consideration. They will clearlycommunicate decisions and rationale openly and in a timely
manner. Once a decision is made, the leader and membersof the team will all be accountable for the results and for
implementing the decision rapidly.

AMGEN BY THE NUMBERS*
Thousand Oaks,
California
Headquarters

1980

Year Founded~24,000
Employees$26B

Total Revenues$4.8B

R&D Investment

Number of Countries
Where Products Are Sold:~100

Stock Listing

Ticker Symbol

NASDAQ

AMGN

Amgen is also a member of the Dow Jones Industrial Average.

*As of December 31, 2021.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

2021 AWARDS AND RANKINGSDOW JONES SUSTAINABILIT Y INDEX
Amgen ranked among the top biotech companies in corporate
responsibility with its inclusion on the Dow Jones Sustainability Indices(DJSI) World Index for the eighth year in a row. Amgen was also included
on the DJSI North America Index for the ninth consecutive year.
AMERICAN HEART ASSOCIATION
Amgen ranked as one of the leading companies in the United States
for workplace health and wellness in the American Heart Association’s
Workplace Health Achievement Index, qualifying for Gold Recognition.
BARRON’S
Barron’s named Amgen to its 100 Most Sustainable Companies list.

NEWSWEEK
Amgen named to Newsweek’s list of America’s Most
Responsible Companies.

BEST PLACES TO WORKCORPORATE EQUALIT Y INDEX
Amgen earned a perfect score of 100% on the
Corporate Equality Index for the fourth year in a row.
MILITARY FRIENDLY EMPLOYER
Amgen named a Military Friendly Employer, qualifying for
Silver Recognition.

JUST 100 LIST
Amgen named to the list for the fourth consecutive year.
TRÈS HAUTE QUALITÉ SOCIALE ET
ENVIRONNEMENTALE ( THQSE)
Amgen is the first pharma company in France to receive the Silver
Medal ranking in the THQSE award, given to companies committed
to sustainable development and environmental health.
FORBES
Ranked among America’s Best Employers for Diversity andranked among America’s Best Employers for New Grads.

5 | E N V I R ON M E N T A L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

LEADERSHIP MESSAGE
I am pleased to introduce Amgen’s
latest Environmental, Social, andGovernance (ESG) Report.
Amgen’s commitment to good ESG
practices dates back to our founding
more than four decades ago.
Throughout our history, Amgen has
contributed to society in many ways –most importantly by bringing
innovative medicines to patients withserious disease, but also by supporting our employees and theirfamilies, contributing to the well-being of our local communities,
and operating our business in an ethical, environmentally
responsible, and socially inclusive manner.
As you will learn from this report, Amgen has made considerable
progress during the past year with our ESG performance.
On the environment, we announced our aspiration to achieve
net zero carbon emissions in our operations by 2027, along witha 40% reduction in water use and a 75% reduction in waste
disposed.1 We also announced plans for new manufacturing
facilities in North Carolina and Ohio that will utilize cutting-edge
technologies to be much more efficient and environmentallyfriendly than traditional plants. Finally, renewable energy sources
provided 79% of Amgen’s total electricity consumption in
2021, up from 41% in 2020. In February 2022, Amgen issued its
first-ever “green bond,” raising $750 million to support our 2027
environmental sustainability aspirations.

Turning to social performance, we continued our efforts toimprove the diversity of our workforce, and we supplemented
our traditional benefits by providing additional mental healthresources to support our colleagues worldwide in this challenging
time, including programs focused on the pressures facing
communities of color. Through our RISE (Representation in
Clinical Research) Initiative, we continued working toward
increasing the ethnic and racial diversity of participants in clinical
trials of our investigational medicines. Amgen is a founding
sponsor of the OneTen coalition, a coalition of many of theworld’s largest, best-known companies seeking to advanceour shared goal of recruiting one million Black Americans intofamily-sustaining jobs over the next ten years, with a focus on
people lacking traditional four-year college degrees. In addition,Amgen pledged to double the amount of business we do withdiverse suppliers in the United States and to triple our businesswith Black-owned suppliers by 2023.2
To expand access to our treatments, some $2.2 billion3 of our
medicines were provided at no cost to uninsured or underinsured
patients in the United States through the Amgen Safety Net
Foundation,4 and Amgen provided 900,000 daily doses of our
medicines at no cost in more than 20 low- and middle-income
countries through our partnership with Direct Relief. To inspire
the next generation of innovators, in 2021 the Amgen Foundation4
supported science education programs that reached over 27
million students and educators worldwide, and it provided
some $3 million to support racial and social justice initiatives,
economic empowerment, and equal opportunity in education.
Carbon neutrality goal refers to Scope 1 and 2 emissions. Reductions take into accountonly verified reduction projections, do not take into account changes associated with thecontraction or expansion of the Company and are measured against a 2019 baseline.
2
Measured against a 2019 baseline.
3
Valued at wholesale acquisition cost.
4 
The Amgen Safety Net Foundation and The Amgen Foundation, Inc., are separate legal
entities entirely funded by Amgen.
1

6 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

With respect to governance, Amgen has a diverse andindependent Board of Directors, elected annually by a majorityof our stockholders. Our lead independent director has robust
and well-defined responsibilities, and only independent Board
members serve on key committees. Amgen has adopted anumber of practices that increase stockholders’ share of voice inour governance, including proxy access for director nominations
and enabling stockholders to act by written consent and callspecial meetings. In 2021, we included ESG performance in
our Company goals under our annual incentive compensation
plan, and we are developing a wide range of external
disclosures—including this report—to communicate frequently
and transparently on our ESG performance.
I invite you to explore this report to learn more about Amgen’s
ESG performance. We are pleased with our progress and eager
to do more.

Robert A. Bradway,
Chairman and Chief Executive Officer

Throughout this report, you will see indicators ofAmgen’s alignment with key components of the UN
Sustainable Development Goals and the UN Global
Compact. Amgen remains committed to its principles
and to reporting on our progress in implementing them.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

OUR APPROACH TO ESG
Amgen’s approach to corporate responsibility starts with our mission to serve patients and is executed through our ESG framework.
Our ESG efforts are grounded in our mission to serve patients,from our endeavors to strengthen science education andinspire the next generation of scientists, to expanding accessto our medicines and supporting efforts to strengthen
healthcare systems to better serve patients in need worldwide
while also pursuing a more environmentally sustainablebusiness model. While our Company is very focused on thefinancial and data-driven metrics of our ESG programs, we
also value the true human impact of our business, andstrive for a strong culture of inclusion and belonging.
Amgen’s ESG Framework is built on four strategic pillars:
Healthy People, Healthy Society, Healthy Planet, and A
Healthy Amgen. This framework facilitates our ability toaddress the interconnectivity of issues in a holistic way
across our business and integrate these activities more closely with our long-term strategy.
In 2021, to further integrate ESG across the organization,
we added an ESG target to our Company-wide performancegoals within our annual incentive compensation plan.

ESG GOVERNANCE
The Amgen Board of Directors and its applicable committees
oversee Amgen’s ESG strategy and activities. The Corporate
Responsibility and Compliance Committee (CRCC) assists
the Board with oversight of Amgen’s activities in areas that
7 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

include environmental sustainability; diversity, inclusion andbelonging (DI&B); and access to medicines. In 2022, oversightof DI&B shifted to the Board’s Compensation and Management
Development Committee, the committee that also provides
oversight of our approach to human capital management.
The Governance and Nominating Committee oversees
the Company’s corporate governance activities and Board
membership. The Audit Committee provides oversight ofour disclosure processes in support of our ESG reporting.
Amgen’s executive management provides regular updates
to the Board and its committees regarding the status andprogress of the Company’s ESG activities.
Our cross-functional executive-level ESG Council sets
and reviews the Company’s ESG strategy and programs.
The Council is chaired by the Senior Vice President ofCorporate Affairs.
Four initiative steering committees (ISCs), each aligned with
one of our four strategic pillars, support the ESG Council.
Each ISC coordinates the implementation of the strategy for
its respective pillar and integrates our ESG strategy into theCompany with the support of subject-matter-expert working
teams. ISC members identify emerging ESG issues that could
impact Amgen’s business, employees, communities or
stakeholders and, when appropriate, raise them with the
ESG Council for discussion and analysis.

Amgen Inc. Board of Directors
Oversees Amgen’s ESG Strategy and Activities
Key Committees
Corporate
Responsibility& Compliance
Committee

Compensation& Management
Development
Committee

Governance& Nominating
Committee

Audit
Committee

Executive Management
Provides the Board and its committees with updates on
the Company’s ESG strategy, performance, and priority areas
ESG Council
Sets and reviews the Company’s ESG strategy and programs
Healthy
PeopleHealthySociety

Healthy
PlanetA Healthy
Amgen

Initiative
Steering
Committee

Initiative
Steering
Committee

Initiative
Steering
Committee

Initiative
Steering
Committee

Working
Teams

Working
Teams

Working
Teams

Working
Teams

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

AppendixOUR

ESG Framework

IDENTIFYING HIGH-PRIORITY ESG TOPICS
Amgen uses a variety of analytical tools to identify,
evolve, and monitor ESG topics, including:•	Periodic stakeholder perspective assessments,
which analyze the perspectives of both internaland external stakeholders.
•	Direct and indirect interactions with stakeholders,
including investors, patients, healthcare professionals,
and patient advocacy organizations.

Healthy
PeopleHealthySociety

Healthy
PlanetA HealthyAmgen

We focus on removing
barriers that limit equitable
access to healthcare sothat people can live theirhealthiest lives.

We work toward a morejust society for our
employees and thepeople we serve.

We prioritize sustainability
and aim to minimize ourenviromental impact
to preserve natural
resources for generations
to come.

We hold ourselves tohigh standards in ouroperations - working
to ensure our culture
and products reflect
Amgen Values.

Diversity, Inclusion &Belonging

Environmental
Sustainability

We also review relevant ESG reporting standards andframeworks, such as the Biopharma Investor ESG
Communication Guidance, SASB and TCFD.
In 2021, Amgen conducted its most recent stakeholder
perspective assessment. Using the results of this assessment,
as well as the information gathered through stakeholder
engagement and the other analytical tools and reviews
described above, our current ESG priorities are shown to
the right in relationship to the four strategic pillars.

8 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

Key Program Elements•	Review of the alignment and integration of ESG with
Amgen’s strategy, mission, and values.

Health Equity
Access to Medicines

Responsible Sourcing

Corporate Philanthropy
Ethical Research

GovernanceBusiness Ethics

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

ALIGNMENT WITH SUSTAINABLE DEVELOPMENT GOALS
As a global biopharmaceutical company focused on improving human health and advancing science, we recognize the powerful role we can playin not only supporting, but contributing to the achievement of the United Nations (U.N.) 17 Sustainable Development Goals. Through our corebusiness and investments by the Amgen Foundation, we believe we can most meaningfully contribute to the following five U.N. goals.

The pursuit of good health andwell-being is embedded in Amgen’s
mission: to serve patients. We
believe that discovering, developing,
manufacturing, and delivering
innovative therapeutics that address
serious diseases will not only help
patients, but also will help reduce
the social and economic burdens ofdisease on society. We also support
the health, wellness, and safety of
our employees globally, and wework to ensure that our suppliers
do the same.

Expanded access to quality scienceeducation is at the heart of the Amgen
Foundation’s activities. Throughprograms and partnerships, theAmgen Foundation seeks to advancescience education, including among
low-income and disadvantaged
students. Since it started operating
in 1991, the Amgen Foundation has
committed over $200 million to
support science education
programming globally, and, with
our partners, reached millions ofstudents with high-quality
science-based learning tools
in the classroom and online.

Innovation is core to Amgen’s
business. In addition to using
innovation to develop pioneering
medicines, Amgen applies innovation
to our drug development operations
and manufacturing processes. The
demonstrated environmental
benefits of our next-generation
biomanufacturing processes are
one example of the value of ourinnovative approaches.

We aim to achieve carbon neutrality
in our operations, while reducing
water usage (by 40%) and waste
disposed (by 75%) by 2027.5
We expect to make significant
investments over time to achievethese aspirations, building on ourpast success. In 2021, we worked torecycle—and divert from landfills—
over 2,200 pounds of masks used byour employees and visitors to oursites. We also donate used lab
equipment and office furniture to
nonprofit organizations andeducational institutions.

Carbon neutrality goal refers to Scope 1 and 2. Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of
the Company and are measured against a 2019 baseline.

5 

9 | E N VIRON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

Much of what Amgen accomplishes
is through partnerships, sponsorships,
and collaborations such as thosewith the nonprofit patient support
organization Lazarex Cancer
Foundation, medical assistancenongovernmental organization
Direct Relief, OneTen, a nonprofit
organization focused on closing theopportunity gap for Black talent
in America, and the nonprofit
educational organization Khan
Academy. We remain focused on
joining with diverse stakeholders totackle significant challenges fromclimate change and health inequity
to gender equality and education.

Introduction

COVID-19 Response

Healthy People

Healthy Society

COVID-19 RESPONSE
As the pandemic continued in 2021, we remained vigilant in our efforts to protect employee
health and safety and ensure ongoing supply of our medicines to patients worldwide.

1 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Healthy Planet

A Healthy Amgen

AppendixIntroduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

COVID-19 RESPONSE
In the second year of the COVID-19 pandemic, we continued to monitor and counter risks to our staff, business and communities in which we operate.
In addition, we are integrating key learnings into our ongoing pandemic preparedness planning.

Using a science-based and data-driven approach, Amgenprioritized staff health and safety to help ensure businessresilience and deliver on Amgen’s aspiration to serve every
patient every time globally.
Ensuring Employee Health and Well-Being
While many staff worked from home during 2021, we put inplace additional measures to help ensure the safety of ouremployees and contractors working at our manufacturing
and research sites who were vital to our ability to supply
needed medicines to patients and advance new products
and product candidates. We adjusted these measures asadditional staff returned to offices when local conditions
allowed. We required all U.S. employees, contractors, andvisitors to complete a digital daily wellness check before
entering an Amgen site and implemented digital close-contact
tracking devices at several of our major sites to quickly andefficiently identify exposure cases. We also continued periodic
testing at our offices in the United States, indoor masking,enhanced cleaning procedures and physical distancing.

1 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 RESPONSE

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

For employees working from home in the United States andother countries, we continued to provide a monthly stipend
for broadband Internet access along with an allowance topurchase necessary home-office equipment.
We continued to make mental health resources available
at no cost to all employees and their dependents, as wellas education support, discounts on childcare and academic
tutoring services, online learning resources, and additional
Company-wide paid days off. And we provided managers
with resilience training to help them assist their teams
through this period of change. Employees have connectedwith each other through our Employee Resource Groups
at an unprecedented rate over the pandemic, bolstering
connectivity and embracing a culture of inclusion (readmore on page 29).

In 2021, Amgen hosted an on-site vaccination clinic at its largest manufacturing
facility in Juncos, Puerto Rico, where more than 1,000 staff members received theirfirst dose of the COVID-19 vaccine. Despite the challenges of the pandemic, the site
maintained full production capacity throughout 2020 and 2021.

During the first half of 2021, as scientific evidence grew
showing overwhelmingly that widespread vaccination
was the most effective measure to protect communities
from serious illness and limit the spread of COVID-19, wedeveloped a dedicated COVID-19 vaccine internal webpage
and education materials for staff and leaders to enhancegreater awareness of the benefits of vaccines. We
implemented a requirement for U.S. and Puerto Rico staff
and certain contractors, particularly those working at oursites, to be fully vaccinated by November 1, 2021.6 We
strongly encouraged staff outside of the United States
to receive the COVID-19 vaccination when it became
available to them.

A Healthy Amgen

Appendix

As countries began to reopen in 2021, Amgen country
leaders determined when and how their teams would returnto the workplace in alignment with local guidelines. Moving
forward, we will follow a new, more flexible workplaceapproach globally, based on lessons learned during the
pandemic and employee feedback. Learn more about our
new approach on page 34.
Supporting Patients and Healthcare Providers
Clinical trials are a critical step in our development of new
medicines. Despite the challenges presented by COVID-19,
we remain focused on supporting our active clinical sites
in their providing of care to patients and in our provisionof investigational drug supply.
Throughout the pandemic, Amgen Manufacturing operations
have never stopped working to ensure the continued supplyof our medicines to patients. In addition, we have contributed
our manufacturing expertise to the fight against COVID-19.
Through a collaboration with Eli Lilly and Company, we arecontributing to the production of their COVID-19 therapies, aneffort that began in 2020 and continued in 2021.
We also continued to provide healthcare professionals
with the information they needed to prescribe our
medicines appropriately. While we leveraged newtechnologies and digital tools prior to COVID-19, thepandemic accelerated our efforts.

This vaccination requirement did not apply to staff who were unable toreceive a COVID-19 vaccine because of qualifying medical or religious reasons.

6

1 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 RESPONSE
Supporting Communities During COVID-19
Building on our efforts in 2020 when Amgen and the Amgen
Foundation committed up to $12.5 million to support COVID-19
relief efforts, in 2021 the Amgen Foundation donated an
additional $1.25 million to organizations continuing to assist
countries around the world. Our support in 2021 included a$500,000 grant to Direct Relief, helping them provide portable
oxygen concentrators to hard-hit India. The Amgen Foundation
also matched staff donations to Direct Relief, Project Hope,International Medical Corps, American India Foundation,
CARE, Ekal Vidyalaya Foundation of USA, and Oxygen for
India for COVID-19 relief and recovery efforts. In addition,Amgen donated COVID-19 testing equipment, consumables
such as thermometers and gloves, and personal protective
gear to those on the front line and at greatest risk.

$1.25M

donated to organizations
assisting countries battling COVID-19

COVID-19 Response

Healthy People

Healthy Society

1 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

A Healthy Amgen

Appendix

Helping Iceland Control COVID-19
Through Genetic Research
As early as July 2020, world health officials were praising theefforts of Iceland in its control and prevention of COVID-19.
Meanwhile, healthcare officials in the country itself werepraising the contributions of Amgen´s subsidiary in Iceland,deCODE Genetics, for its support in helping them get aheadof the rapidly spreading virus.
In 2020, researchers at deCODE began working with the
Icelandic government to screen for COVID-19 among
those who were asymptomatic and those diagnosed andsymptomatic. They then sequenced the virus from all
diagnosed with COVID-19 and continued doing sothroughout 2021. To date, Iceland is the only country in
the world where COVID-19 has been fully sequenced in
all patients diagnosed with the virus.
According to health officials, this large scale and early testing
conducted by deCODE gave the country the information it
needed to tailor its response to the pandemic.
“It is evident now that deCODE’s screening gave us valuable
insight into the situation,” said Iðunn Garðarsdóttir, Political
Advisor to Icelandic Health Minister Svandís Svavarsdóttir.7$500,000

grant to Direct Relief,
helping them provide portable oxygen
concentrators to hard-hit India

Healthy Planet

7

Controlling and Preventing Infection Spread in Iceland.

Based on the data collected, deCODE completed studies
of both humoral and cellular immunity against COVID-19,
publishing results in two papers in the New England Journalof Medicine. It also studied the long-term consequences ofthe virus, developing models for assessing the impact ofvaccination against the COVID-19 virus and its spread among
the unvaccinated.
MORE INFORMATIONCOVID-19 Response

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y P E O P L E
We focus on removing barriers that limit equitable access to healthcareso that people can live their healthiest lives.

2021 Highlights

Provided approximately

Provided

$2.2B

$147M

*

of Amgen medicines at no cost to uninsured
or underinsured patients in the United States
through the Amgen Safety Net Foundation*of Amgen medicines at no cost
to underserved patients in more than
20 low- and middle-income countries since 2018

Contributed$11.7M
in funding to support
health equity activities*Valued at wholesale acquisition cost.

1 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y P E O P L E
For more than 40 years, Amgen’s commitment to science and innovation has helped patients live longer, healthier lives.
We support initiatives to advance health equity so that more people can experience the benefits of science, including
through improved access to life-saving medicines and care. We use a portfolio of approaches to address challenges toaccess, working with governments, patient groups, civil society, and other partners.
Our approach includes:•	
Making our products more accessible through responsible

AMBITION
Our commitment to patients,
science, and innovation motivates
us to work to remove barriers that
limit equitable access to highquality medicine and healthcare.
These barriers are present aroundthe world, but they vary significantly
by geography and community, andtend to be particularly highin those communities that havebeen historically underserved.

pricing, patient support programs and targeted
donation programs.
•	
Addressing underlying social factors that can have a greater
impact on health than clinical factors.
•	Working with partners to strengthen health systems andsupport health equity by•	Enhancing the knowledge, skills, and expertise of health 		workers to deliver proven, science-based care.
•	Supporting patients throughout their healthcare journey, 		from diagnosis and screening to treatment adherence.
•	Educating patients and improving health literacy.
•	Increasing the representation of racial and ethnic
minority patient populations in clinical trials.
•	Strengthening community and care support systems that
impact access to healthcare for underserved communities.

This section includes:

ACCESS TO MEDICINESHEALTH EQUIT Y

1 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

ACCESS TO MEDICINESVALUE CREATION
Providing access to our
medicines is an extensionof Amgen’s mission toserve patients.
Through our access to medicines programs,
we work with partners to expand accessto our medicines and support efforts tostrengthen healthcare systems to better
serve patients in need worldwide.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Appendix

Amgen’s medicines make a difference for those facing serious illnesses, and together with partners
and stakeholders, we are working to overcome access challenges and improve care capabilities
through a multifaceted approach tailored to the unique aspects of biologic medicines.
Our Approach to Responsible Pricing
Every day, we work to discover, develop and deliver
breakthrough medicines that make a difference to patients’
lives and address some of society’s most serious diseases.
Innovative medicines offer our best opportunity to effectively
manage disease and contain long-term healthcare costs,
which is why Amgen prices its medicines responsibly,
partners with payers to align on value, and develops patient
support programs to help ensure broad access to our novel
therapies for appropriate patients.
Amgen understands that the cost of prescription medicines
is a concern for many people. We are committed to the
responsible pricing of our medicines by considering theireconomic and social value and the clinical and economic
burden of diseases. In each of the years since 2018, theaverage net price for Amgen medicines has declined.
In addition to responsible pricing, Amgen has implemented
value-based contracting to help improve patient access toinnovative medicines and offer stakeholders greater budget
predictability. Also, our high-quality biosimilars are backed
by four decades of biologics expertise and can potentiallyoffer more affordable, life-altering treatment options that
contribute to the sustainability of our healthcare system.
LEARN MORE ABOUT
Amgen’s Approach to Responsible Pricing

1 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

A Healthy Amgen

Patient Support Activities
The Amgen Safety Net Foundation (ASNF)8 supports
qualifying patients in the United States who might gowithout important medicines because of financial barriers.
In 2021, the commercial value of the Amgen medicines
provided at no cost to uninsured or underinsured patientsby ASNF was approximately $2.2 billion.9
Outside of the United States, we continued to offer
financial patient support programs in 20 middle-income
countries designed to help clinically and financially eligible
patients obtain the medicines they need while they await
reimbursement. These programs limit patient out-of-pocket
costs for certain treatments, including for multiple
myeloma, giant cell tumor of the bone, homozygous
familial hypercholesterolemia, metastatic colorectal
cancer, cancer-related bone complications, and acutelymphoblastic leukemia.
Working With Partners to Reach Patients
In 2021, our longtime partner Direct Relief distributed
Amgen products we donated to support underserved
patients in more than 20 countries, from Haiti and India to
Liberia and Syria. In total, medicines donated provided morethan 900,000 daily doses of treatment to patients.

Amgen Safety Net Foundation is a separate legal entity funded solely by Amgen.
Valued at wholesale acquisition cost.

8
9

Introduction

ACCESS TO MEDICINES“Direct Relief is honored to partner with Amgen as we
support the provision of innovative therapies to patientsliving in medically underserved areas that lack regularaccess to their required therapies,” says D. Thomas Roane,
Vice President, Corporate Engagement & Strategy at Direct
Relief. “The Amgen donation enabled tens of thousands ofunderserved patients to access the medicines they required.”In 2022, Amgen is partnering with Direct Relief to support
a new global initiative to improve the health and lives ofpeople suffering from breast cancer. The Comprehensive
Breast Cancer Initiative seeks to expand access to breast
cancer education and treatment, including Amgen
medicines, for women living in less-developed countries.
It will also support investments in cancer care infrastructure
and workforce, including in diagnosis, treatment, palliative
care and supportive care.
Amgen and Direct Relief will also work with the City Cancer
Challenge Foundation in 2022 to advance access to cancer
care through evidence-based decision-making.

1 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Expanding Access to BLINCYTO® to Those in NeedIn 2021, Amgen, together with St. Jude Children’s Hospitaland Direct Relief, continued to expand the BLINCYTO
Humanitarian Access Program (BHAP). Launched in 2020
in India, the program expanded in 2021 to an additional
hospital in India treating pediatric cancer patients with
B-cell precursor acute lymphoblastic leukemia (ALL) andto Pakistan. We expect to further expand this program in
2022 with the addition of a new hospital in Vietnam. ALL is
the most common form of leukemia in children and, if left
untreated, can be fatal within weeks. Under BHAP, carefully
selected and qualified hospitals receive BLINCYTO at no cost,
together with medical training and ongoing support of safe
administration and patient care.

impact of a cancer like ALL is devastating for“ The
children and their families, and we hope that theaccess to BLINCYTO brings much needed hope tothese patients as they continue their treatment.

”

DARRYL SLEEP
Chief Medical Officer at Amgen

A Healthy Amgen

Appendix

Cold storage for temperature sensitive therapies are staged at Direct Relief’s
warehouse before being shipped. (Lara Cooper/Direct Relief)

WORKING WITH PARTNERS TO
STRENGTHEN HEALTH SYSTEMSAND ADVOCATE FOR BETTER CARE
In addition to working with our partners to help expand
access to our medicines, Amgen collaborates with advocacy
groups to address the underlying barriers of access andimprove health outcomes for patients around the world.
Below are a few recent examples.
Building Resilient Health Systems in Europe
COVID-19 disrupted healthcare systems around the world,
making it difficult and, in some cases, even impossible formany people to access diagnostic services. Delayed diagnosis
can have life-threatening impacts on people living withcancer who, if not diagnosed promptly, may be unable tobenefit from treatment.

Introduction

ACCESS TO MEDICINES

To help address this challenge, in 2021, Amgen sponsored
two reports on the collateral impact of COVID-19 on
cancer diagnosis in Europe. The reports included policy
recommendations to help nations reduce wait times forcancer care caused by COVID-related delays, build more
resilient healthcare systems, and better weather future crises.
In partnership with the European Cancer Organization, theUK’s National Screening Committee, the European Cancer
Patient Coalition, and other groups, IQVIA Institute for Human
Data Science hosted webinars to share findings from thereports with more than 1,000 attendees in over 70 countries.
“There is a positive message from the pandemic–if there isa will, there is a way. All the stakeholders have the possibility
to act together and do something for better diagnosis andscreening,” said Alfonso Alguaron, a patient advocate in
Spain, during the Cancer Won’t Wait webinar.
READ THE REPORTS:

WATCH THE WEBINARS:

Cancer Won’t Wait Report
Cancer Won’t Wait Webinar
Lung Cancer Won’t Wait Report Lung Cancer Won’t Wait
Elevating Awareness of the Risk of
Osteoporosis in Mexico
Many women may not know they are living with postmenopausal osteoporosis and are at risk of life-threateningbone fractures. In Mexico, many are unaware of the condition,as screening is infrequent and not consistent across the country.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Since 2019, Amgen has worked with medical societies,
healthcare providers, and members of government to help
elevate the visibility of osteoporosis as a public health issue andbuild consensus around screening, diagnosis, and treatment
protocols, including for post-fracture and secondary prevention.
In 2021, these collaborative efforts reached a key milestonewhen seven leading medical societies reached agreementon osteoporosis detection and treatment practices. With
support from Amgen, their recommendations were presented
in a special congressional forum of the Mexican Senate
and published in a leading clinical journal. Following theagreement, Amgen sponsored workshops and a social media
campaign called “Unbreakable Together” to help build awarenessof the recommendations and new treatment protocols amongauthorities and healthcare providers in the country.

Appendix

ACCESS TO
MEDICINES DATA
Amgen Safety Net Foundation
Value of medicines provided at no costto low-income patients in the United States
through the Amgen Safety Net Foundation$2.2B*

Helping Migraine Sufferers in JapanAn estimated 8.4 million patients in Japan suffer from
migraines, with more than one million patients believed
to be in need of treatment. One challenge many patients
face is difficulty finding a headache specialist due tospecialist shortages. In addition, many patients find it
difficult to see a specialist due to work and caregiving
responsibilities. This challenge was compounded by
COVID-19, which made face-to-face consultation evenmore difficult.

$1.4B*$1.5B*

20192020

Direct Relief
Value of medicines provided at no cost in
low- and middle-income countries throughDirect Relief from 2018 through 2021

$147M*

Partnering with MICIN, Amgen launched a pilot program toassess the usefulness of telemedicine for patients in Japanliving with migraines. Findings from the pilot demonstrated
that telemedicine can help patients manage their care.
Amgen is also working with the Japanese Headache Society
to continue to support the needs of migraine patients.

MORE INFORMATION Access to Medicines
Valued at wholesale acquisition cost.

*

1 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

2021

Introduction
Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

STRENGTHENING PEDIATRIC CANCER CARE IN TANZANIA
The vial filled with a critical $500 cancer treatment for a sickchild in Tanzania was delivered in what amounted to a picnic
cooler stuffed with ice. It might as well have arrived empty.
The humid, subtropical climate had already taken its toll.
Dr. Trish Scanlan said the medicine, which must be kept at atemperature between 2 and 8 degrees Celsius, had arrived
from Dar Es Salam in the loose, insecure package. Over thehours on its journey, the medicine had warmed. It was useless.
“An absolute disaster,” Scanlan said. “It meant the cancer was
getting a break in a child who needs that medicine now.”For Scanlan, director of the nonprofit children’s cancer
charity Tumaini La Maisha, seeing medicine being wasted
was too much.
In 2021, she found help through a California-based nonprofit,
Direct Relief, and Amgen. Both stepped in, supporting
Muhimbili National Hospital and Tumaini La Maisha with acold room that cost nearly $20,000 that keeps medicines atthe low temperatures needed. Direct Relief is also supplying
Tumaini La Maisha with 50 thermal packages that can bereused for up to five years, while Amgen is donating $12.5
million10 worth of oncology supportive care medicine.

MORE INFORMATION Access to Medicines

High-Tech Packages
The thermal packages began arriving in Tanzania in April.
Mike Wooten, Direct Relief cold chain specialist, said the boxes
that will carry the cancer treatments are a mix of high-end

data technology and old-school durability that shouldn’t pose
any problems for shipping medicine overnight in Tanzania.
Each package, about 8 liters, has a battery-operated datalogger to keep track of the temperatures as the box istransported, to make sure the medications inside never go
above the ideal temperatures. He said the packages are goodfor about 80 hours in worst-case weather. Meanwhile, thecold storage unit will enable bulk purchases for medications
without fears of spoiling.
The Work
Scanlan said about 4,000 children in Tanzania will develop
cancer each year, but less than a quarter of those currently
seek care. She said the arrival of the cold chain supplies willallow more children to get life-saving treatment and spend
less time in the hospitals.
“We can send boxes of chemo every week and look after
the children in the peripheral areas,” Scanlan said. “Thatmeans the children have to spend far less time of their lifein the hospital and can be at home with their family
between treatments.”
As a cancer survivor herself, Scanlan knows the pain andstruggle of the fight. She said she won’t be satisfied until the
thousands of children suffering with cancer in Tanzania all
have access to treatment.
That’s the work. And the mission. One child at a time.
10

1 9 | E N V I RON M E N TA L , S O C IAL & GOVERNANC E REPORT 2 0 2 1

Valued at wholesale acquisition cost.

Introduction

HEALTH EQUIT Y

COVID-19 Response

Healthy People

Healthy Society

There are significant opportunities to improve the healthof all people through understanding and addressing
health disparities present in our communities, particularly
in key therapeutic areas such as oncology, cardiovascular,
and inflammation. Improving health equity requires
addressing both barriers to medical care and social
determinants of health.

VALUE CREATION
Addressing health disparities
helps to expand access tosolutions and improvehealth outcomes for people inunderserved communities,
while also allowing us to build new
relationships and gain unique perspectives
and understanding that will allow us
to better meet the needs of suchpatients in the future.

Healthy Planet

A Healthy Amgen

Appendix

Amgen is working to advance policies and practices insupport of achieving health equity so that all people havean opportunity to maximize health outcomes. This includes
efforts to improve representation in clinical trials and provide
comprehensive health education to underserved patients,
as well as advocating for policies and programs that support
accessible and inclusive healthcare and working withpartners to give rise to underrepresented voices.

OUR VISION
Advance policies and practices in support of achieving health equity sothat all people have an opportunity to be as healthy as possible

OUR FOCUS AREAS
Representative
product development

Comprehensive
health education

Accessible andinclusive healthcare

OUR OBJECTIVES

Expand access to and participationin clinical trials and develop
medicines to address unmet
needs among historicallyunderserved patients

2 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Improve health literacy andeducation among historicallyunderserved patients

Strengthen community and care
support systems and access to
medicines for historicallyunderserved patients

Introduction

HEALTH EQUIT Y
Raising the Spotlight on Health Inequities
In 2021, we partnered with a national health equity advisorygroup of state legislators from 16 U.S. states and four
national caucuses of color—the National Black Caucus ofState Legislators, the National Hispanic Caucus of State
Legislators, the National Asian Pacific American Caucus ofState Legislators, and the National Caucus of Native American
State Legislators—to support bipartisan dialogue on healthequity. Through a series of town hall discussions andeducational resources, we are working to support policychange that will address barriers to care facing historicallyunderrepresented communities.
“Together we can work toward a country where yourbackground, your ZIP code and your income do not
determine whether you have access to quality affordablecare,” said Congressman Raul Ruiz, MD, U.S. Representative
for California’s 36th Congressional District and Chair of theCongressional Hispanic Caucus, at the 2021 Amgen Health
Equity Summit.
At our 8th Annual Health Equity Summit we focused on
disrupting health disparities through partnership. The virtual
event included more than 500 participants from sevencountries representing patient advocacy organizations,
physician associations, medical institutions, academia, andthe private sector. Discussions from the summit yielded
five key takeaways.
2 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

HEALTH EQ UI T Y S UM M I T
FI V E KE Y TAKEAWAYS
COVID-19 has broughtyears-old health equity issues
to the forefront.

Healthy Planet

A Healthy Amgen

Appendix

Working to Increase Diversity and Improve
Representation in Clinical Trials
The underrepresentation of racial and ethnic minority
patients in clinical trials contributes to the collection ofincomplete or limited trial data, limited access to innovative
treatment for vulnerable populations, and disparities inhealth outcomes. Barriers to participation include mistrust,lack of awareness, logistical challenges such as transportation,and provider bias.

SOCIAL CARE & DIGNIT Y
sit at the heart of health equity.

Racial and ethnic minority groups have been underrepresented
in clinical trials vs. the proportion of the general populationthat they represent.

COMMUNIT Y-BASED
services form a foundation toaddress health inequities.

•	Black Americans bear a disproportionate share of the cancer
burden, having the highest death rate and the lowest survival
rate of any racial or ethnic group in the U.S. for most cancers.
Yet according to the U.S. Food and Drug Administration(FDA), in 2019 alone, of the participants in oncology trials,
73% were White, 18% were Asian, 4% were Black Americanand 5% were Hispanic.

TECHNOLOGY IS A TOOL
and a challenge in addressing
health disparities.

PATIENT-CENTRIC,CULTURALLY SENSITIVE
approach to care is critical.

•	Black Americans are 30% more likely to die from heartdisease than non-Hispanic Whites, but they make up only
2.5% of cardiovascular disease clinical trials.
•	Black and Hispanic Americans patients suffer
disproportionately from severe asthma. However,they are often underrepresented within clinical trialsof asthma therapies.
Amgen is working to improve the proportional representationof trial participants in clinical trials by addressing key systemic
issues that deter people from participating in research,Introduction

HEALTH EQUIT Y
especially those groups who have been historically excluded
due to race, ethnicity, sex, age, and other factors. Amgen’s
Representation in Clinical Research team, also known as
RISE, is working to address these barriers. In 2021, RISE led
engagement with representatives of historically underserved
and excluded communities through a series of productagnostic community advisory boards. This helped us obtaininsights and perspectives on best practices for engagementwith these communities more broadly, with the goal of building
long-term, sustainable relationships. We will continue to seek
guidance from key community advisors to help ensure that
our efforts resonate with community needs and highlight
community members’ voices.
In 2021, we developed, with input from RISE, an enterprise-wide
framework to strengthen our focus on enhancing diversity
and representation in clinical trial participation across ourportfolio. In addition, we have developed diversity plans for
multiple clinical studies that align with industry principles
and FDA guidance for industry to enhance diversity inclinical trials and encourage inclusivity in medical productdevelopment. In early 2022, Amgen announced its support
for the CEO Roundtable on Cancer’s new multiyear initiative
Going for Gold. This initiative will work with Historically Black
Colleges and Universities and Hispanic Serving Institutions
to improve health equity, education, navigation, and access.
Oncology Leaders Take Action to Curb Lack of Diversity in Clinical Trials.
Improving Diversity and Inclusion in Cancer Clinical Trials and Research.

11 
12

2 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

The program is expected to positively impact more than 20
million lives, especially among communities disproportionately
affected by cancer. Through the initiative, universities cancontribute to research efforts through the CEO Roundtable’s
Project Data Sphere®, which helps expand access to clinical
trial research and offers an open-access digital platform for
aggregating and analyzing data to advance health equity efforts.
Increasing Access to Oncology Trials for
Underrepresented Communities
Recent data from the FDA show that, of total participants inclinical trials for oncology products that led to approvals,

A Healthy Amgen

Appendixjust 4% were Black participants and 5% were Hispanic
participants, despite the fact that, during this same period,
13.4% of the U.S. population was Black and 18.1% was
Hispanic.11 This is even though Black, Indigenous, and Peopleof Color overall in the United States have both the highest
death rates and shortest survival rates for most cancers.12
Amgen is investing in programs to increase scientific datawith the goal of changing these numbers.
One way to contribute to this change is by bringing historicallyunderrepresented patients into clinical trials conducted
where they live, such as in community clinics where four

RISE is working to exceed industry standards for clinical trial diversity and representationand to help Amgen develop new medicines studied in participants who better reflect the
populations impacted by certain diseases or conditions.

TH REE- YEAR P L A N / SI X P I L L A R S

Evolve the way
we design andrun clinical
trials, focusing on
people who havebeen historically
excluded fromclinical researchPartner withclinical trial
investigators who
are representativeof the participants
they are aiming
to recruit

Bring theresearch
directly to thecommunities
where people
live and work

Change how
researchers
communicate
with patients,
caregivers,
and providers

Enhanceprecision
medicineawareness andimprove genetic
diversity intranslational
scienceCollaborate
with national
andcommunityorganizations

Introduction

HEALTH EQUIT Y
fifths of cancer patients in the United States are treated. To
reach these patients—many of whom are from lower-income
backgrounds—we established the Amgen Community
Oncology Research Collaborators program. This initiative
makes it easier for community oncologists at more than 200
sites across the United States to refer their patients to studiesof Amgen’s investigational cancer medicines. Since its inception
in 2018, we have offered oncologists at sites participating in
the program more than 65 new clinical trial opportunities fortheir patients, representing a 2,100% increase.
We are also supporting a study led by the Leukemia &Lymphoma Society and the University of Florida to develop
and assess the effectiveness of a novel online training program
designed to increase primary care providers’ understandingof cancer clinical trials and their capacity to encourage patientsto inquire about clinical trials when making treatment decisions.
The study will include 400 providers who predominantly
treat patients underrepresented in clinical trials. Study results
are expected by early 2023.
Through support from Amgen, our longtime partner the
Lazarex Cancer Foundation recently launched several
innovative community-based Cancer Wellness HUBs in
partnership with the University of Southern California’s
Norris Comprehensive Cancer Center. These HUBs bringexisting cancer education and awareness efforts directly to

2 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

residents of underrepresented and vulnerable communities.
This partnership is designed to provide residents ofunderserved communities with access to the latest
available research, information about current clinical trials,
technology, access to available lifestyle improvement
programs, and opportunities to optimize health outcomes.
They also offer a safe space for residents to talk about healthconcerns, including disease prevention, survivorship, andend-of-life issues. One of the key goals of the HUBs is toconnect patients to clinical trials.
“The Lazarex Cancer Foundation is helping raise awarenessof the benefits of clinical trials for many here in Los Angeles,”said Freddie Muse Jr., a prostate cancer survivor and founderof The Men’s Cancer Network in Los Angeles.“This is especially
important for people of color, many of whom have concerns
and misconceptions about trials based on historical incidents.
The Men’s Cancer Network is working with Lazarex, to not
only change mindsets, but to help our community navigate
access to trials. Lazarex is helping our network get reimbursed
for the costs associated with travel to and from clinical trials,
lodging, and meals—seemingly small, but potentiallysignificant, barriers to access for many.”
Addressing Health Equity Through Comprehensive
Health Education
Historically underrepresented populations have lower
rates of screening and diagnosis for many life-threatening
conditions—from cancer and heart disease to osteoporosis
and rheumatoid arthritis. Delays in diagnosis in some casesmean patients do not receive access to potentially life-saving
treatments until it is too late, leading to higher mortality
rates for underrepresented and underserved populations.

A Healthy Amgen

Appendix

One group at risk is Black women who have undergone
treatment for breast cancer and may be at an increased risk
for osteoporosis and bone fracture. For the second year ina row, Amgen partnered with the Tigerlily Foundation toraise awareness among young women, women of color, andunderserved communities regarding bone health and its
impact specifically on breast cancer patients. Througheducation and multimedia efforts, the campaign reachedmore than six million people.
We are also working with TOUCH, the Black Breast Cancer
Alliance, to help the Black breast cancer community
advocate for the best healthcare possible. Amgen is
supporting Touch’s “The Doctor is In: Bone Health Campaign,”
that includes a weekly web series, and a #LoveYourBones
social media campaign to connect women to educational
blogs, resources, and events featuring testimonials and tips
for maintaining healthy bones.
Working to Raise Health Awareness Through Trusted
Community Leaders
Religious leaders are among the most trusted membersof local communities, providing vital information on social
services, education, and health to their congregations. We
work with the Health Education Advocacy Learning (HEAL)
collaborative, which partners with faith-based organizations
to help make communities of color healthier.
Amgen is supporting a number of HEAL initiatives inGeorgia, Ohio, Texas, and Maryland to raise awareness of
diseases that disproportionately affect undeserved
communities and people of color, including osteoporosis,

Introduction

HEALTH EQUIT Y
lung cancer, prostate cancer, and multiple myeloma. The
program includes information on risk factors, channels
for accessing care, and seeks to raise awareness about
participating in clinical trials for potential treatments.
“Our work with Amgen has put a spotlight on diseases
that most people, including those from underrepresented
communities, have cursory or no knowledge at all about
symptoms, let alone available screenings or clinical trials,”said Howard Mosby, who serves as one of the leaders of
HEAL. “Amgen has proved through its work with us that it
is not interested in checking off boxes, but wants to see theneedle move as a result of education and policy change.”
Addressing Social Determinants of Health
Recent data13 show that disparities in cardiovascular risk
factors between Black and White adults in the United States
may be largely attributable to social determinants of health.
To improve our understanding of this issue, Amgen partneredwith Humana to conduct a study among patients who havebeen hospitalized for cardiovascular-related conditions.
Social determinants of health can have a greater impact
on health outcomes than clinical factors, especially within
underserved populations.

2 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

Barriers most often reported by respondents included foodinsecurity, financial strain, housing quality, and transportation
barriers. In terms of the groups most likely to face social
determinants of health barriers, 68% of White survey
respondents reported no social needs, while more than half(54%) of Black survey respondents reported at least one
social need. Amgen and Humana will use the findings to
identify, implement, and evaluate potential interventions.

Beyond cardiovascular health, we are also exploring
interventions to address barriers to care in other therapeuticareas, working with local community providers and otherpartners. For example, in 2021, we established a partnershipwith Findhelp.org, a community network referral programthat helps people find financial assistance, food pantries,
medical care, and other free or reduced-cost services intheir local communities.

Social and economic factors drive an estimated
40% of health outcomes – twice as influential asfactors related to clinical care.14

2021 PERFORMANCE DATA

$11.7M

Not addressing social determinants of healthadds at least 5% to total health plan costsin the United States.15
We also collaborated with our longtime partner the American
Heart Association in 2021, launching a three-year grassroots
program that will raise awareness of cardiovascular healthand prevention strategies while engaging and supporting
community members to create a culture of health. The
platform, EmPOWERED to Serve, will provide “healthy living”
lessons to underresourced communities in California, Florida,
Indiana, Nevada, North Carolina, Ohio, Pennsylvania, andTexas. The program accelerates innovative solutions toeliminate disparities in underresourced communities causedby social determinants of health by leveraging local healthambassadors to help spread awareness about heart disease,stroke and the importance of a healthy lifestyle.

Funding contributedin support ofadvancing healthequity activities

60

Number oforganizations
funded82

Number of
projects
fundedMORE INFORMATION
2021 Amgen Health Equity Summit e J, Zhu Z, Bundy JD, Dorans KS, Chen J, Hamm LL. Trends in Cardiovascular
H
Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status,
1999-2018. JAMA. 2021;326(13):1286–1298.
14
World Health Organization.
15
Aetna CVS Health.
13

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y S O C I E T Y
We work toward a more just society for our employees and the people we serve.

2021 Highlights

Announced a new, moreFLEXIBLE
WORKPLACEAPPROACH

2 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

The Amgen Foundation
reached more than

27M

students and educators worldwide throughits four core science education programs

In a staff listening survey, “Leaders demonstrate a

VISIBLE COMMITMENTTO DIVERSIT Y”
was rated as a top strength

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y S O C I E T Y
At Amgen, we are working to attract and retain a wide diversity of people from different backgrounds, cultures,
educational experiences, and religions because we believe that a workforce that reflects the diversity of our customers
and communities fosters innovation, which supports our ability to serve patients and their communities.
OUR STRATEGY INCLUDES:
Attracting talent from diverse candidate pools
and considering the full breadth of what anindividual’s background and experience can bringto a role at Amgen, while striving to eliminate
potential bias from the decision-making process.

AMBITION
We value and are focusedon doing our part to build
a more just society, starting
within our own workplace.

Providing staff members with mentorship,
sponsorship, and career development
opportunities to help them achieve theirfullest potential.
Continuing to develop practices around pay,promotions, and performance managementwith a focus on enhancing equity throughout
the organization.
Emphasizing and working to respond to
the personal well-being and mental healthof our staff.
Endeavoring to create a work environment
where each employee is able to bring theirwhole self to work, to have their voice heard,
and to feel a sense of belonging.

2 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Beyond Amgen, we are working with community leaders
to explore and address deeply rooted barriers to economic
prosperity, equity, and social justice, as well as expand
economic opportunities within the communities in which
we operate. We are also working with teachers and otherpartners to reimagine science education, improve science
literacy, and empower diverse thinkers. And, we are engaging
with diverse suppliers and supporting local communities
through job creation with the potential for better wages.
This section includes:

DIVERSIT Y, INCLUSION& BELONGINGHUMAN CAPITALMANAGEMENTCOMMUNIT Y INVESTMENTRESPONSIBLE SOURCINGIntroduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

DIVERSIT Y, INCLUSION& BELONGING
We are on an ongoing journey to become a more diverse and inclusive organization that recruits, develops, and retains a workforce representativeof the global communities we serve. This journey requires deliberate and consistent action to address longstanding challenges and bring us to abetter place, together. Beyond Amgen, we are engaging with business and other community leaders, government officials, and external partners
who share our desire to promote social justice and equity.

OUR PRIORITIESVALUE CREATION
We believe that an environment ofdiversity, inclusion, and belonging
fosters innovation, strengthens ourglobal workforce, and drives ourability to serve patients.
We believe that our global presence isstrengthened by having a workforce thatreflects the diversity of the patients we serveand maintaining an environment in whichsuch diversity contributes to our mission.

2 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

GLOBAL• Increase the representation anddevelopment of women in executive
director and above roles.

UNITED STATES• I ncrease the representation ofBlack people in science, technology,
engineering, and mathematicsbased roles.
• Increase the representation anddevelopment of Black and Hispanic
people in executive director andabove roles.

Introduction

DIVERSIT Y, INCLUSION& BELONGING
Hiring, Developing, and Retaining Diverse Talent
Amgen is a founding member of OneTen, a coalition of manyof the world’s largest companies that aims collectively to hire
one million Black Americans into family-sustaining jobs overthe next 10 years, with a focus on those without a four-yearcollege degree. Near our global headquarters, we participatedin the launch of the Los Angeles OneTen partnership. Amgen
CEO Bob Bradway is serving as the CEO leader for the Los
Angeles partnership, working to bring other like-mindedorganizations into the coalition.
We expect that the hiring of 750 people from a diverse talentpool in two new sites approved in 2021, Ohio and North
Carolina, will help support our OneTen commitment. We also
expanded our work with Historically Black Colleges andUniversities (HBCUs) by broadening our partnership with
Howard University on a new educational and research
fellowship (See page 32).
In an effort to increase women and minorities in leadership
positions, our recruitment providers are expected to provide
us with diverse candidate slates for all executive-level positions
and we monitor their performance on this commitment.
Within our workforce, we support the development ofdiverse talent through several initiatives, including a

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

formal 1:1 executive mentoring program, function-specificleadership development programs, and peer mentoring
networks through our 11 Employee Resource Groups (ERGs).

More than

1,000
WOMEN

have been mentored throughour Women Empowered to
Be Exceptional (WE2) ERG
peer mentoring program.

Since its inception in 2003, WE2 has grown to be Amgen’s
largest ERG with 24 chapters and thousands of members
around the globe. In 2021, WE2 launched a mentoring program
designed specifically to help connect high-performing womenof color with senior leadership and provide opportunities foradvocacy and sponsorship. Read more about our ERGs below.
We analyze performance ratings, promotions, base pay, andtotal compensation of our staff as part of our efforts to drive
equity in our workplace.
Activating a Culture of Inclusion and Belonging
Our focus remains on building a more diverse, inclusive
Amgen, where our workforce feels a sense of belonging
and can achieve their full potential.

As of December 31, 2021, 98% of staff worldwide completed Managing Unconscious Bias training, which is now mandatory for all new hires. Unconscious Bias
training is recommended, but not required, for staff members in Spain, the Netherlands, Italy, France, and Germany per guidance from the EU Works Council.

16 

2 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

A Healthy Amgen

Appendix

After introducing Managing Unconscious Bias training, which
was completed by 100% of our employees in the UnitedStates, Puerto Rico, and Canada in 2020, we expanded therequired online course to staff around the world in 2021.16
We also embedded unconscious bias scenarios in our annual
Code of Conduct training.
In 2021, as part of our Company-wide goals under our annual
incentive compensation program, we introduced an ESG
goal focused on environmental sustainability and diversity,
inclusion and belonging (DI&B). The DI&B portion of this ESG
goal focused on the establishment and completion of DI&B
action plans by our executives, with a target goal of 75%
participation, which we exceeded.

In our year-end
employee listening survey,

77% OF STAFFSURVEYED

indicated that top leadersdemonstrate a visible
commitment to diversity.

We also continued to make new learning resources available
on our DI&B learning portal, focused on key behaviors needed
to create an environment in which diverse teams can flourish
and deliver for the patients we serve.

Introduction

DIVERSIT Y, INCLUSION& BELONGINGCOVID-19 Response

Healthy People

Healthy Society

Healthy Planet

ERGs also provide cultural perspectives that are helping to
inform Amgen leadership and our strategic initiatives. In
2021, ABEN leaders met bimonthly with senior leadershipto support recruitment efforts, report on Amgen actions
and advocacy in local communities, and provide insightand support for the Amgen Foundation’s social justice grant
making (see page 30). ERGs are also supporting Amgen’s
efforts to address healthcare equity; in 2021, the Amgen
Asian Association joined ABEN’s ongoing collaboration with
the RISE Team to increase diverse representation in clinical
trials. See page 21 for more information.

am proud to see the great work the Amgen Black“ IEmployee
Network Brazil team has been doing

Embracing Connectivity and Diverse Points of View
Through Our ERGs
In 2021, membership in our 11 ERGs increased 41% froma year earlier, and employees formed nine new global ERG
chapters. In total, there are more than 60 Amgen ERG chaptersaround the world.
During 2021, ERGs hosted events to address relevant
issues, such as parenting during the pandemic, and createdresources such as a new podcast, The Brain Trust, developedby the Amgen Black Employee Network (ABEN) to build staff
understanding and empower conversations about race inthe workplace.

2 9 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

to raise awareness of racial inequalities in ourcountry and taking actions to change it. Dealing
with racism and other types of discriminations
and prejudices are urgent tasks and critical increating a diverse and inclusive environment
where people feel they belong. DI&B strategies
are also essential for us to accomplish our mission
to serve patients.

”

ANA ARANTES, ABEN Brazil Leader

A Healthy Amgen

Appendix

Supporting Mental Health“The pandemic and ongoing racial and social justice protests
led us to reimagine and amplify mental health support forour staff, as many were mentally exhausted by the increasein racial hate incidents, particularly in the United States,” said
Derek Miller, Senior Vice President, Human Resources.
In response to ongoing racial and social injustices
experienced by staff members in 2021, we created a DI&B
online wellness portal where staff could find more than 20
well-being and mental health resources.

Introduction

DIVERSIT Y, INCLUSION& BELONGING
Helping to Build a More Just and Equitable Society
In 2021, the Amgen Foundation provided grants totaling $3
million to nearly 40 U.S.-based nonprofits in support of racialand social justice initiatives, economic empowerment, andequal opportunity in education. This included support to• Stop AAPI (Asian American and Pacific Islander) Hate,a reporting and resource center. This center tracks andresponds to incidents of hate, violence, harassment,
discrimination, shunning, and child bullying against Asian
Americans and Pacific Islanders in the United States.
• Thurgood Marshall College Fund, which is dedicatedto transforming the lives of students at HBCUs andPredominantly Black Institutions.
• Education Trust to help highlight racial disparities inparticipation in advanced placement (AP) science courses
in U.S. high schools, and identify opportunities to build
foundational skills in middle school that will prepare
students for success in AP-level biology, life sciences,and other STEM disciplines.

3 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet• National Urban League, which works to elevate the standardof living in historically underserved urban communities.
Supporting Future Leaders
As part of our support of social justice and equal opportunity,
in 2020 the Amgen Foundation provided $7.5 million in
grants to support social justice and equal opportunity tonational organizations and local organizations in U.S.
communities where Amgen operates. One of the recipients
was Thrive Scholars, which provides high-achieving, lowincome students of color with six years of academic andmentoring support from high school to early career.
With this 2021 grant from the Amgen Foundation, Thrive
Scholars provided additional support to students interested
in the life sciences, technology, and engineering, and also
piloted a STEM Capstone project. Through the project,
80 incoming high school seniors in a variety of locations
participated in real-world consulting projects, helping tonurture their interests and skills in STEM. The organization
also kickstarted a program with STEM companies to provide
mentorship opportunities to Thrive Scholars as well as
potential internships.
In 2021, the Amgen Foundation also came together withleading scholars to support the launch of a new collaborative
effort with LabXchange, a free online science education
platform supported by the Amgen Foundation and Harvard
University. This latest effort is designed to empower sciencelearners and educators to recognize and help rectify the

A Healthy Amgen

Appendix

structures that sustain racial inequity in medicine, education,and STEM fields in the United States. For more informationon this and other initiatives we support that seek to remove
barriers to access to science education, see page 37.

Scholars are the type of students best
“ Our
positioned to diversify the leadership of the STEM
industry,” said Steve Stein, Thrive Scholars CEO.
“But without a program like ours—and partners
like the Amgen Foundation—many will not.
Through our new model, Scholars receive tailoredcollege admission guidance for STEM college
programs, STEM-specific academic preparation
prior to college, social-emotional and academic
support geared to the rigors of STEM majors, and
STEM-focused career training—setting them on acourse for success not only in college but in life.

”

STEVE STEIN, Thrive Scholars CEO

Introduction

DIVERSIT Y, INCLUSION& BELONGING

Stamping Out Unconscious Bias
“Unconscious bias in the workplace
disproportionately impacts underrepresented
or underserved groups and reduces workplace
productivity. Such biases create barriers that
not only prevent people from working together
effectively, but also damage the trust andrespect in relationships that help foster
creativity and innovation.”
Excerpt from scenario in Amgen Code of
Conduct employee training module

MORE INFORMATION
Amgen’s Commitment to Diversity,
Inclusion and Belonging
Although we do not use our Federal Employer Information
Report EEO-1 to measure progress, we make our mostrecent filing publicly available. For more information
around the composition of our workforce, please go to
our 2021 Workforce Diversity Report.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

2021 DI&B DATA

17

51%

52%

WOMEN 18

MINORITY(U.S./P.R.)

Women in total workforce18

Ethnic minority in workforce

Ethnic minority in workforce(U.S./P.R.)(U.S./P.R.)

100%

100%

100%

80%

80%

80%

60%

49%

40%

60%

44%

20%

40%

60%

44%
32%

20%

Managementlevel19

Executive
level2040%
20%Managementlevel19

Executive
level20

25%

20%
4%
Asian

Black/
AfricanAmerican2%
Hispanic/
LatinoOther21

Data as of December 2021. To align with U.S. government reporting requirements, data in this document use the traditional gender categories of male and female. We deeply respect that gender is not binary; reporting in this manner should not
represent our position on the issue. Totals may not add up to 100% due to rounding or employees who have not reported their gender and/or race/ethnicity.
Data based on total headcount as reported in our Form 10-K for the year ended December 31, 2021, modified to reflect active employee headcount, which, among other things, excludes co-ops and interns. Also excludes Gensenta Pharmaceuticals
and deCode Genetics.
19
Management: Senior managers and directors.
20
Executive level: Executive directors and above.
21
Other: American Indian/Alaska Native, Native Hawaiian or Pacific Islander, two or more races, or not specified.
17 

18 

3 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

NEW FELLOWSHIP PROGRAM BETWEEN AMGEN AND
HOWARD UNIVERSITY AIMS TO EXPAND TALENT POOL

“It was the excitement of connecting
science to the real world,” O’Neal says.
“It wasn’t magic or ambiguous. It was
relatable to everything.”
Her passion was fueled by a mother who held a math degreeand made sure O’Neal took advanced classes, enrolled herin summer camps centered on science and took trips to
Dr. Johnson’s house. Dr. Johnson, a family friend, often let hercome to a lab to see chemistry experiments in action and it
thrilled her.

PILAR O’NEAL loved science from an early age, doing
dissections or investigating the ingredients in everyday
household items to understand the chemistry that madethem what they were.

3 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

“This program exemplifies our commitment to improving
diversity and inclusion throughout Amgen and our Research &Development organization,” said Alan Russell, Vice President,
Research at Amgen.“We hope it will serve as a flagship to expand
to other departments at Howard University and other HBCUs.”
During the first year of the program, students will be atHoward working with mentors from the Howard University
Department of Chemical Engineering. During the second
year, they will be onsite at an Amgen location for six months
working on research projects.
Bram Estes, a senior scientist in biologics at Amgen, is O’Neal’s
mentor, working with her on a project connected to DNA protein
co-delivery into cells and intracellular routing and uptake of
biologics. He has high hopes for both the project and O’Neal.

That path was solidified through high school and college
as O’Neal earned scholarships and science awards andobtained her bachelor’s degree in chemical engineeringfrom Howard University.

“I would like her to publish her research in the Amgen-Howardcollaboration, both to advance science and to establish her
reputation in the scientific community,” Estes said. “This projectis the beginning of what I hope will be a great career.”

In 2021, she took another step – working towards a master’s
degree and joining Amgen as a part of the Amgen Educational
Fellowship at Howard University in its inaugural year. The
program provides its fellows further insights into a careerin science, including what a career at Amgen looks like andunderstanding the Company’s interest in adding diversity to
its research ranks.

O’Neal agrees. When she completes the program in two years,
she will have her graduate degree and, she hopes, a chance tofulfill a lifelong dream – to contribute to the world of science.
“My goal is to help my community and to help humanity,” O’Nealsays. “So maybe one day, even if I help just a few people, I’ll havemade a positive impact on the world.”

Introduction

HUMAN CAPITALMANAGEMENTVALUE CREATIONOur global presence isstrengthened by our ability
to attract, retain, and promotea diverse workforce of talented
and engaged employees whobelieve in our mission and values.

3 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

At Amgen, it is our staff that bring innovation to life and make us who we are—a leader in serving patients.
We seek to recruit, develop, and retain the best and thebrightest from an array of fields and diverse backgrounds.
We work to provide our employees the skills and careerdevelopment they need to build meaningful careers andtools to support their total wellness. We also invest in thesafety of our staff and work to help ensure compliance withall applicable international human rights standards withinboth our own operations and those of our suppliers.

TALENT MANAGEMENT AND DEVELOPMENT
We help our employees at every level build and strengthenskills required to meet the evolving needs of our business,
as well as advance into new roles. Our online learning hub
is accessible to all staff globally and includes resources forskills development, playlists based on topic areas such as
manager effectiveness and time management, podcasts,
and articles. Within the United States, Canada, and Puerto
Rico, we offer a tuition reimbursement program, which
reimburses participating full- and part-time staff members
for college tuition, books, and specified exam and registration
fees (up to plan limits). We also offer a manager training
curriculum to prepare new managers to lead and inspire
their teams. At leadership levels, we have an annual process
to help identify and develop talent and prepare future
leaders. Our consistent process has resulted in a strong
internal pipeline of leadership talent that we draw onwhen hiring or replacing key leadership roles.

BUILDING OUR DIGITAL MUSCLE
Accelerating digital innovation is an Amgenpriority. Critical to the program’s success ishaving highly skilled Amgen staff equippedwith capabilities in data science, software anddata engineering, automation, information
security, and other areas requiring complex
problem-solving skills.
We are investing to help our current employees
strengthen their digital skills through fully
reimbursed certification programs, as well as
online courses. And we are accelerating ourrecruitment of candidates with this highly
sought-after digital expertise. To help in ouroutreach to new candidates, we asked ourcurrent staff working in digital to talk about
their experience and what life is like at Amgen.
You can hear their stories here.

Introduction

HUMAN CAPITALMANAGEMENTEMPLOYEE HEALTH AND WELL-BEING
From our competitive compensation programs to ourprogressive benefits and wellness programs, we work hardto support the health and well-being of our employees andtheir families.
Our approach to employee compensation and benefits isdesigned to deliver cash, equity, and benefit programs thatare competitive with those offered by leading companies inthe biotechnology and pharmaceutical industries to attract,
motivate, and retain talent.
All regular U.S. staff members are eligible to participate in thesame core health and welfare and retirement savings plans.
U.S. employee benefits include medical, dental and visioncare plans, retirement savings plans, employee assistanceprograms, adoption assistance, paid parental leave programs,
access to childcare, an employee stock purchase plan,
healthcare and dependent care flexible spending accounts,
business travel accident insurance, short- and long-term
disability benefits, wellness programs, and work-life resources
and referrals. Globally, comparable benefit programs areoffered with the same health and well-being goals, while
also designed to comply with local statutory requirements.
To learn more, visit our website.

3 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Support for Employees’ Emotional Well-being
All U.S.-based Amgen employees have accessto an enhanced behavioral health program thatprovides employees and their dependents withmental health care. Staff outside the United States are eligible
for behavioral health support consistent with national healthprograms in their respective local country and/or via a
supplemental program sponsored by Amgen. Employees
can use the program for a wide range of outpatient
behavioral health conditions, including stress, anxiety,postpartum and other types of depression, relationshipconcerns, and sleep disorders.
Globally, we also offer mental health training and education
to Amgen managers to help them notice and respond tostaff possibly in need. In addition, we make available toour general workforce meditation and mindfulness
programming, resilience training, mental and behavioral
health workshops, and parenting support resources.
Employee-Centered Health Programs
We offer a variety of programs to help our
employees better manage a range of healthconditions from breast cancer to migraines.
Many offer convenient ways for employees to manage theircare. For example, employees with high blood pressure cantrack, manage, and improve their heart health from theirphone with an app-based program and blood pressure
monitor available at no cost to eligible healthplan members.

A Healthy Amgen

Appendix

WORK-LIFE BALANCEThe COVID-19 pandemic has brought employees’ needand desire for flexibility and support for work-life balance
to the forefront like never before. Companies like Amgenthat realize this will be on the leading edge in talent
recruitment and retention.
As pandemic restrictions eased around the world in 2021,
we announced a new, more flexible workplace approach,based on lessons learned during the pandemic andemployee feedback. Our new, global approach encourages
eligible employees to choose the workplace best suited totheir work, while coming to an Amgen site for activities that
benefit from face-to-face collaboration, networking, andrecognition events. Many of our employees can also choose,with manager approval, to work fully remote from anywhere
within their existing assigned country.
“This was a pivotal moment, an opportunity to reimagine thefuture of working at Amgen,” said Bob Bradway, Amgen CEO.
“Our goal is to empower our global workforce to work when
and where they are most productive, while also providing
the flexibility to achieve work-life balance.”
For many years, Amgen has supported the need for staff
flexibility, including the times surrounding life events such as
the birth or adoption of a child. We heightened our support
for working parents during the pandemic by offering
additional access to resources for tutoring and childcare
services. We also offer staff members access to college

Introduction

HUMAN CAPITALMANAGEMENT
advisory services, as well as resources to assist staff with eldercare responsibilities. Amgen continues to offer subsidized,
onsite childcare at our larger Company locations.

able to be with my newborn daughter for“ Being
several weeks after she was born in 2021 not only
provided invaluable bonding time, it also helped
me support my wife and my other children, allof whom were home due to the pandemic. It
allowed me to unplug and be in the moment.
As my children continue to grow, it is reassuring
to know that I have the ongoing support of mymanagement and colleagues during this busy life
stage. For me, family-friendly policies like parental
leave are important factors for why I workat Amgen.

”

DENNIS YAI, Senior Cousel at Amgen

3 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

HUMAN RIGHTS
Amgen believes in the inherent dignity of every humanbeing, regardless of where they live or were born, theireconomic status, their religious beliefs, their race, their sexual
orientation or expression, their disability status, or their gender
identity. Amgen grounds this belief in its mission to serve
patients and in its support of the key tenets of the United
Nations Universal Declaration of Human Rights.
We expect our suppliers to uphold the same human rightsof their workers. Through our supplier assessment program(see page 42), we monitor our suppliers’ compliance with our
Supplier Code of Conduct and internationally recognizedhuman rights standards, including those that seek to prevent
forced and child labor, support fair pay based on applicablewage laws, and allow for freedom of association.
For more information, see our Human Rights Commitment
statement.

EMPLOYEE SAFETY
Our aspiration is for an accident-free workplace. Throughcomprehensive safety programs and ongoing education andtraining, we strive to maintain a robust safety culture for all
employees and minimize work-related injuries, illnesses, andincidents. Our safety policies are based on the U.S. Occupational
Safety and Health Administration standards.

A Healthy Amgen

Appendix

All employees undergo safety training during new-hireorientation and annually through our required Code of Conduct
training. We also conduct regular safety engagement
discussions between supervisors and frontline workers in
our manufacturing and research facilities where expectations
and feedback are exchanged. We encourage employees tooffer safety observations and improvement suggestions
during these discussions or through a Safety Event Evaluation(SEE) card.
We track injuries and near-miss incidents in an online incident
tracking system. In addition, we conduct a formal executive
management review of functional safety performance for
our Operations, Global Commercial Operations, and Researchand Development facilities on a quarterly basis with afocus on identifying early signals and taking action to drive
continuous improvement.
While many Amgen staff continued to work from home in
2021, safety did not take a back seat. We conducted homeergonomic assessments for many staff, identifying equipment
such as ergonomic chairs, standup desks, and external monitors
to help staff work safely and comfortably. Amgen purchased
identified equipment at no cost to our employees.
We also implemented telematics tracking for our U.S. sales
fleet as part of our driver safety program. Telematics helps us
detect certain driving behaviors such as speeding and harshbraking. In 2021, our collision rate declined (an improvementof 8% year over year). In addition, better driving habits
typically translate into reduced fuel use, which is better forIntroduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

HUMAN CAPITALMANAGEMENT
the environment. With the help of telematics and other fleet
safety investments in previous years, we have reduced ourcollision rate by 37% over the past five years.
Within our manufacturing operations, we implemented
human error prevention training to help facilitate ouractively caring culture. These tools are used by staff andmanagement to openly discuss concerns and eliminate
barriers to safe performance through a “raise your hand”
mindset. These discussions allow teams to systematically
identify and resolve small issues before they becomelarger problems.
MORE INFORMATION
Wellness at Amgen
Safety at Amgen
Environment, Health, and Safety Policy

A Healthy Amgen

Appendix

2021 PERFORMANCE DATA
Amgen hosts an annual safety summit for
employees, and 2021 was no different. What
was different was the increased focus on
nurturing a psychologically safe environment.
Through discussions, Amgen leaders exploredways to incorporate psychological safety
within their teams.

Recordable Incident Rate
Amgen
Staff

Amgen Staff
Target (0.27)

Contractors
Target (0.40)

Contractors

0.62
0.5
0.4
0.31

0.31
0.19

2019

2020

2019

2021

2020

2021

Lost Day Case Rate
Amgen Staff

0.12

0.08

0.09

Contractors

0.27

0.17

0.25

Amgen Staff

0

1

0

Contractors

0

0

0

Fatalities

Motor Vehicle Safety (collisions per million miles)
Fleet

3 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

4.40

3.38

3.09

Introduction

COMMUNIT Y INVESTMENT

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

AppendixThrough the Amgen Foundation, we are reimagining science education to improve science literacy
and empower diverse thinkers to develop solutions to humanity’s biggest challenges.
The Amgen Foundation is guided by the belief that everyone
needs science, and science needs everyone. By broadening
access to engaging and inspiring science programs, we areworking to equip future generations with the essential skills
needed to thrive in our increasingly complex world. Working
with trusted local and global partners, our aim is to

VALUE CREATION
Investment in scienceeducation helps build thefuture pipeline of innovatorsand scientists the world willneed to tackle global
challenges, from climatechange to pandemics.
It also helps to build scientific literacy, which is
critical to our industry, society, and public health.

	Inspire the next generation of scientists and foster
future problem solvers—wherever they are.
	Engage students with diverse perspectives andbackgrounds by helping to remove barriers toaccess to quality science education.
	Support the development of best-in-classscience education resources at no cost toteachers and students, particularly low-income
and disadvantaged learners.
We are doing this through our four signature scienceeducation programs, described below.
Since 1991, the Amgen Foundation has committed
more than $200 million to advancing science education
programming globally, reaching tens of millions of students
and teachers. In 2021 alone, the Amgen Foundation reachedover 27 million students and educators worldwide throughits four core science education programs.

3 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COMMUNIT Y INVESTMENT

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

LabXchange has helped teachers remain connected,
especially during the pandemic. Uma Mahajan, a secondary
educator, notes how “COVID-19 has really pushed teachers
to rethink their teaching strategies.”“A top priority for me was to make my classroom resources
equitable for all students,” she says. “LabXchange allows
students to progress at their own pace. And because I cantailor my lessons to fit my classes, it is an outstanding
differentiation tool.”
LabXchange Provides Resources to Examine Racismin Public Health, Science, and Education
With the support of a $1.2 million grant from the Amgen
Foundation in 2021, LabXchange launched a groundbreaking
project designed to explore and address the structures thathave perpetuated racial inequity in healthcare, education,and STEM fields in the United States.

LABXCHANGE
Launched by the Amgen Foundation and Harvard University
in 2020, LabXchange is a free online science education
platform that provides users with access to personalized
instruction, virtual lab experiences, and networking
opportunities across the global scientific community.
Through $13 million in grants to date from the Amgen
Foundation, LabXchange reached over 12 million users
in 2021, of which more than 80% were in low- or lowermiddle-income countries. LabXchange offers more than
13,000 learning experiences from over 140 different
collaborating organizations.
3 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Under the guidance of an expert faculty steering committee,
graduate student fellows from HBCUs and other institutions
are authoring new digital learning resources for high school
and college educators. Resources, which will be made freely
available in English and Spanish, will focus on•	Racism as a Public Health Crisis: Increasing publicawareness of racial health disparities and teaching
critical thinking skills needed to dismantle structuresthat perpetuate inequities.
•	Inclusive and Antiracist Teaching Strategies: Providing
evidence-based practices to support Black students’ senseof belonging, identity, and success in science; andculturally responsive teaching, as well as strategies toincrease participation and leadership in science from
historically underrepresented and underserved groups.

A Healthy Amgen

Appendix

LABXCHANGE IMPACT
Users
Worldwide

Collaborators

2020

191,317

81

12.4M

3.8M

59

2021

Hours ofEngagement

2020

133,487

2021

2020

2021

years ago in my essay ‘Why We Should“ Twenty
Teach Our Students About Race,’ I opined
about the completely ineffective K-12 approachconcerning human biological diversity. Thanks
to LabXchange and the Amgen Foundation, we
now have a plan to rectify this.

”DR. JOSEPH L. GRAVES JR., renowned evolutionary
geneticist, and faculty steering committee member
for the Racial Diversity LabXchange project

For more information, visit the Racial
Diversity, Equity and Inclusion in Science
Education project on LabXchange.

Introduction

COMMUNIT Y INVESTMENT

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

One of the schools supported by Khan Academy is Hueneme
Elementary, in Port Hueneme, Calif., where 84% of students
qualify for free and reduced lunch, and 44% are English
language learners. The district worked with Khan Academy
to set goals and train teachers to help strengthen learning
outcomes through encouraging increased student use of
Khan Academy resources.
“I started to use Khan Academy on a daily basis a few weeks
into lockdown,” says one Khan Academy student. “I had
used it before but I started to use it a lot more in quarantine.
While I liked science before, now I really enjoy learning about‘things that are alive.’ I have gained a greater appreciationof the importance of science and can easily grasp what I’mlearning in school.”

KHAN ACADEMYThe Amgen Foundation is the exclusive sponsor of Khan
Academy’s biology resources, which range from ninth-grade
biology content to Advanced Placement® (AP) biology.
These biology resources reached 15 million students andeducators worldwide in 2021. Khan Academy offers a free,high-quality virtual classroom for students and teachers
around the world.
Since 2015, the Amgen Foundation has committed nearly$7 million to Khan Academy, including to support school
district partnerships during the COVID-19 pandemic. As ofthe end of 2021, Khan Academy has more than 130 million
registered users around the world.

3 9 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

90%

of teachers and students
who have used Khan Academy report it isan effective learning resource.

AMGEN BIOTECH EXPERIENCE
With leadership from university and other partners, theAmgen Biotech Experience (ABE) is a lab initiative thatprovides professional development for science teachers,
teaching materials, and research-grade lab equipment tohigh schools around the world.

A Healthy Amgen

Appendix

Not having the ability to conduct hands-on laboratories
has been a significant challenge for ABE teachers during
the pandemic. Through LabXchange, launched in January
2020 shortly before the pandemic began, ABE teachers wereable to utilize the Foundational Concepts and Techniques in
Biotechnology, a collection of resources including laboratory
simulations built around the core lab techniques of the ABE
program curriculum. The biotechnology resources, available
in 13 languages as of December 2021, are available here.
As the COVID-19 pandemic stretched into 2021, ABE teachers
persisted, adapted, and innovated—finding new ways toengage their students and developing new best practices.
The Amgen Foundation celebrated their resilience and shared
their unique stories in a blog series, which you can read here.

a year of chaos and uncertainty, we are“ Amidst
finding ways to engage, teach, and learn. My
students have banded together to create a safe
haven of hope for their future.

”

KATHERINE SUTTON, ABE Rhode Island Teacher

Introduction

COMMUNIT Y INVESTMENT
ABE Launches Master Teacher Fellowship
In early 2021, based on the feedback of ABE teachers looking
for an opportunity to further their own science learning, theAmgen Foundation and the ABE program launched the ABE
Master Teacher Fellowship. An inaugural cohort of 12 fellows
was selected from 10 countries. Over the yearlong fellowship,with financial support from the Amgen Foundation and accessto Amgen scientists and experts at other STEM-focusedorganizations, each fellow developed their own biotech
curriculum “passion project.” Once final, this resulting curriculum
will be available on the ABE website for use in classrooms
everywhere. Select members of the inaugural cohort willcontinue their Master Teacher engagement by supporting
the second cohort of fellows in 2022. Learn more here.
ABE Volunteers
The ABE Volunteer Program matches Amgen staff withhigh-need ABE high schools to share their career journeys
and describe what they do professionally. Despite the impact
of COVID-19, more than 70 Amgen staff volunteers reachednearly 1,000 students across 32 schools in six Amgen U.S.
communities through virtual classroom visits in 2021. For
students, the program provides diverse role models for arange of biotech careers, as well as real-world context forscience content in the classroom. For Amgen volunteers, it
provides a rewarding and motivating experience.

4 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet“Diversity in STEM needs to be increased by planting theseeds of what is possible as early as possible,” says Krista
Dong, Amgen Scientist and ABE Volunteer. “I’ve also been
generous with their time, thoughts, opinions and feedback.
They have been instrumental in my development as a scientist
and I know that I would not be where I am today without
their support. That is why I choose to volunteer with ABE.”

AMGEN SCHOLARS
Amgen Scholars is an annual summer program that pairs
over 350 undergraduate students from around the globe
with research opportunities at more than 20 world-classinstitutions in the United States, Europe, Asia, Australia, andCanada. Since 2006, Amgen Scholars has supported nearly
4,500 undergraduates from more than 825 colleges anduniversities globally, with many alumni now pursuing
advanced scientific degrees and careers.
Prior to COVID-19, Amgen Scholars supported undergraduatesfrom over 200 colleges and universities annually to conduct
research in-person at 24 academic institutions around theglobe. While the program has had to pivot during the
pandemic, in 2021, we supported 170 Amgen Scholars,
the majority through a virtual experience. This included afour-day virtual global symposium with alumni, biotech
professionals, and academics who discussed various aspectsof the biosciences with Amgen Scholars, including life as a
PhD candidate, science communication, career opportunities
in academia and industry, and more.

A Healthy Amgen

AppendixIntroduction

COMMUNIT Y INVESTMENTCOMMUNITY-FOCUSED GIVING
In addition to science education, the Amgen Foundation
supports local organizations where Amgen employees
live and work, as well as employee-driven philanthropy
with matching gifts and volunteer service programs.
The Foundation also works with partners to support
disaster relief efforts.

AMGEN FOUNDATION HELPSADDRESS HUNGER
In 2021, the Amgen Foundation provided criticaloperating support to the San Francisco–Marin
County Food Bank, which continued to experience
heightened demand for its services due to theimpact of COVID-19. The California nonprofit
addresses hunger head-on by focusing on theimmediate distribution of food while simultaneously
working on long-term strategies to end hunger
and empower neighbors in need. Every week,
over 50,000 local households count on this foodbank for food assistance.

COVID-19 Response

Healthy People

Healthy Planet

Disaster Relief
The Amgen Foundation provides assistance to significant
humanitarian disasters in communities where Amgen staff
live and work. In 2021, this included support in response tohistoric flooding in Europe and devastating tornados in the
United States.
In the aftermath of the devastation caused by Hurricane
Maria in Puerto Rico in 2017, the Amgen Foundation
pledged $3 million to support Hurricane Maria relief
efforts and $2 million for longer-term rebuilding efforts.
In 2021, the rebuilding efforts were completed. Includedin these efforts, the Amgen Foundation along with local
communities, government, and nonprofit partners helped
rebuild eight schools and two universities on the islandthat is home to more than 2,000 Amgen employees.
Giving Tuesday
In 2021, the Amgen Foundation observed Giving Tuesday
by offering a 2:1 match for every $1 donated by Amgen
U.S. and Puerto Rico staff members to eligible nonprofit
organizations. The response from across the organization
was very enthusiastic as ERG members and local teams
helped amplify the event and highlighted worthy charities
within their own teams. At the end of the day, nearly 750
Amgen employees donated almost $900K to over 900 uniquenonprofit organizations. With the Amgen Foundation match, a
total of $2.6 million was donated to nonprofit organizations.
MORE INFORMATION
Amgen Foundation
Amgen Biotech Experience

4 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Healthy Society

LabXchange
Amgen Scholars
Khan Academy

A Healthy Amgen

Appendix

AMGEN FOUNDATION
GIVIN G 22
$31M

$32M

$23M
$21M

2018

2019

2020

2021

22
Since its inception, the Amgen Foundation has
contributed in aggregate more than $375 million.

Introduction

RESPONSIBLE SOURCINGCOVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

Amgen procures goods and services from thousands of suppliers each year. We recognizethat our suppliers are an important part of our value chain that impacts our business andthe communities in which we live and operate.

SUPPLIER SUSTAINABILITYVALUE CREATION
Our ability to deliver lifesaving
medicines depends on a
resilient supply chain.
By strengthening the sustainability performanceof our suppliers, we can reduce our collective
environmental footprint and help ensurebusiness continuity through improved supply
chain conditions. Engaging small and diverse
suppliers not only benefits these suppliers andAmgen, but also uplifts the communities inwhich they operate through job creationand potential for better wages.

Our Supplier Sustainability Program aims to help ensurethat suppliers address not only quality, cost, and reliability
requirements, but also ethical, environmental, and social
considerations, including business ethics, labor, humanrights, and environmental impact. Our Supplier Code of
Conduct sets our fundamental expectations of our
suppliers and is aligned with our core values.
In 2021, we continued our participation in the Pharmaceutical
Supply Chain Initiative, which seeks to promote responsible
supply chain management and better business conditions
across the industry. We also continued our involvement in alife science-specific forum established by EcoVadis, a leading
provider of business sustainability ratings, to strengthen
the sector’s approach to supply chain management with a
specific focus on environmental and social sustainability.

2021 PERFORMANCEDATA
We continued to increase the number ofsuppliers we assessed for ethics, human andlabor rights, and environmental impact.*

~65%

2020

~70%

2021

*Suppliers assessed increased from ~65% of
our total supplier spend in 2020 to ~70% in 2021.

4 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

RESPONSIBLE SOURCING
SUPPLIER DIVERSITY
Through our U.S. Supplier Diversity Program, by 2023 we
aim to double our spend with diverse businesses, including
minority, women, disadvantaged, veteran, and LGBTQ-owned
suppliers and triple our spend with Black-owned businesses.23
In 2021, we participated in numerous external events withdiverse suppliers to share opportunities about working with
Amgen. We also began requiring select key suppliers toreport their supplier diversity spend to us quarterly.

COVID-19 Response

Healthy People

Healthy Society

Shortly after we announced plans to build new manufacturing
facilities in Ohio and North Carolina in 2021 we hosted
virtual supplier forums for diverse suppliers in both locations,sharing sourcing opportunities and information on Amgen’s
Supplier Diversity Program.

2021 PERFORMANCE DATA

35% increasein overall diversity spending
We expanded our supplier mentorship program fromwomen-owned suppliers to minority-owned supplierswith a focus on Black-owned businesses. Through thisprogram, conducted in partnership with local diversity
councils, suppliers engage with senior leaders to learn
more about Amgen.
“Participating in the Amgen Supplier Mentorship Program
shed light on what my agency needs to know to do businesswith large corporations,” said Marci Klein, the owner of Klein
Creative Media.

23

Compared to a 2019 baseline.

4 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Healthy Planet

more thandoubledour spend withBlack-owned businesses

MORE INFORMATION
Supplier Code of Conduct
Supplier Sustainability
Supplier Diversity

A Healthy Amgen

AppendixIntroduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y P L A N E T
We exceeded our goals for carbon, water, and waste reductions in 2021
and are on track to achieve our 2027 ambition.

2021 Highlights

We initiated environmental sustainability

IMPACT ASSESSMENTS
for all capital funding requests as part ofAmgen’s capital funding program.

4 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

For the first time, we

LINKED OUR EXECUTIVE PAY TO
ENVIRONMENTAL SUSTAINABILITY
with the addition of an ESG goal in Amgen’s
annual incentive compensation plan.

We updated Amgen’s
sustainability design standard target for the

LEED CERTIFICATION(Leadership in Energy and Environmental Design),
the most widely used green building rating system globally,
from Silver to Gold.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

H E A LT H Y P L A N E T
Amgen has a longstanding objective to conduct environmentally responsible operations and regularly sets targets to challenge
ourselves to deliver further improvements. Since 2007, we have successfully advanced our environmental sustainability program
while increasing our global production capacity and expanding our presence to approximately 100 countries. Investing insustainable operations also has the potential to improve efficiency and create value.

AMBITION

As a Company committed toadvancing human health, wehave a sense of responsibility topatients, employees and shareholders
to have a positive impact on
the health of our planet.
Reducing our impact on the planet is not only part ofour role as a corporate citizen, it can also bring added
value as energy prices rise and the impact of climate change
further strains access to natural resources. We recognize theclose connection between environmental stresses and healthand the role we can play through our core business.

24

In 2021, we introduced our latest environmental sustainability
program, which we call “The Road to Net Zero”, and announced
a new set of environmental targets. Our 2027 plan includes
the following aspirations:24•	Achieve carbon neutrality for Amgen-owned andoperated facilities and operations.
• Reduce water consumption by 40% from a 2019 baseline.
• Reduce waste disposed by 75% from a 2019 baseline.
To achieve our 2027 goals, Amgen is focusing on theuse of innovative approaches and processes, efficiency
improvements, and increased sourcing of renewable energy.
In addition, while our 2027 aspirations do not incorporate
Scope 3 emissions, we are evaluating the carbon impact fromour value chain—including suppliers, contract manufacturers,
and distributors—to help identify reduction opportunities as
we continue to pursue a responsible sourcing strategy.
We exceeded our goals for carbon, water, and waste
reductions in 2021—and we are on track to achieve our2027 ambition.

Carbon neutrality goal refers to Scope 1 and 2 emissions. Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a
2019 baseline.

4 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

ENVIRONMENTAL SUSTAINABILIT Y

COVID-19 Response

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

Our sustainability strategy embraces innovation, efficiency, and renewable energy
to achieve our 2027 plan.

VALUE CREATIONEXPLORING CLIMATE CHANGE AND LUNG HEALTH

Our investment in environmental
sustainability has not only reduced our
impact on the planet but also allowed
us to be more efficient, productive,
and resilient, resulting in reduced
operating costs.

Drought, wildfires, heat, flooding, and pollution
are already creating serious threats to lung health.
According to recent research by public healthexperts in the United Kingdom, short-term exposure
to elevated levels of air pollution from the burningof fossil fuels can exacerbate asthma, affect lungfunction, and increase respiratory and cardiovascularhospital admissions and deaths. Research also showsthat, far too often, people of color and people living
in low-income communities live and work in places
in areas with increased risks from climate change
and are more likely to have chronic lung disease.25

In addition, as the effects of climate change could
be disruptive to business, we are doing our part todecrease carbon emissions, water use, and waste
disposed and working to reduce the risksof climate-related events to our operations
and to make Amgen a better partner for thecommunities in which we live and work.

As a Company focused on improving health andsaving lives, Amgen is determined to be part of thesolution. In September 2021, we sponsored a virtual
Expert Voices roundtable (hosted by a leading
national news outlet Axios) to hear how stakeholders
from across disciplines are addressing challenges, andto better understand how Amgen can collaborate to25

4 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Healthy People

American Lung Association.

make an impact. Leaders, subject matter experts,
and policy makers from various geographies anddisciplines gathered virtually to discuss the widening
socioeconomic disparities and preventative measures.
They also shared ideas on how to better prepare for
future and long-term effects of climate change onlung health. To read more about the conversation,
visit Axios' event recap here.
Amgen is also seeking to support lung health througha new collaboration with the Asthma and Allergy
Foundation of America (AAFA). The collaboration aims
to help reduce disparities in asthma prevalence,
healthcare utilization and mortality among
underserved, high-risk populations through the
Health Equity Advancement and Leadershipprogram (HEAL). AAFA will work in 2022 with
community-based partners to increase patientknowledge, strengthen patient and physician
communications, and help address asthma symptoms.

Introduction

ENVIRONMENTAL SUSTAINABILIT Y
CARBON NEUTRALITY
Manufacturing
Through innovative manufacturing technologies
implemented at our manufacturing facility in
Singapore , we reduced carbon emissions by 69% and water
use by 54%, as compared to conventional biotechnology
manufacturing.26 In January 2022, we received FDA approval
for a new manufacturing facility in Rhode Island utilizing thesame technologies as our facility in Singapore. In addition,in 2021, we announced plans for the construction of new
facilities in Ohio and North Carolina. At both, we areembedding environmental sustainability into upfront project
design, development, and execution. For example, at our
new multiproduct drug substance manufacturing facility inNorth Carolina, we expect our carbon footprint and water
usage to be substantially lower than at a traditional drug
substance manufacturing plant due to deployment ofinnovative technologies and resource conservation. The site will
use traditional drug substance technologies and Amgen’s
latest innovations to create a facility called FleXBatch.
“This new FleXBatch plant exemplifies Amgen’s approach
to innovative and sustainable biomanufacturing, which—I’m pleased to announce – we are now calling Amgen
EcovationTM,” said Bob Bradway, Amgen CEO.“ This new nameunderscores what is today and has always been distinctive
about biomanufacturing at Amgen: It is highly innovative,
efficient, safe, and environmentally sustainable – all in theservice of benefiting patients with medicines manufactured
according to the highest quality standards.”
4 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

In Ohio, we are building our new final product advanced
assembly and packaging plant to LEED27 standards tomaximize energy efficiency and waste reduction.
Electric Vehicles
By 2027, we plan to convert 30% of our sales fleet vehicles
to electric vehicles (EV).28 In 2021, we launched an EV pilot
program in the United States, the Netherlands and South
Korea, enabling sales representatives and medical liaisons
to upgrade their traditional fuel-operated vehicle to a newelectric vehicle. Our program also includes EV charging
infrastructure improvements in the EV marketplace.
Renewable Energy
The generation and procurement of clean, renewable energy
is an important component of achieving our 2027 carbon
neutrality target.29 Across our network, each Amgen facility
has a portfolio of renewable energy projects. Projects range
from installing innovative renewable energy technologies,
such as onsite solar arrays, to purchasing electricity fromrenewable sources. In 2021, we increased the number offacilities sourcing renewable energy, including our major
North American sites in Rhode Island and our headquarters
in California; our aim is for all Amgen facilities, whereverfeasible, to procure 100% renewable electricity by 2027.
Our carbon neutrality target applies to Amgen-owned and-operated facilities and operations.
At the end of 2021, renewable electricity accounted for 79% of
our total electricity consumption, compared to 41% in 2020.
We achieved this increase in renewable electricity throughthe purchase of renewable energy certificates for electricity
consumption at our North American facilities.

A Healthy Amgen

Appendix

WATER
We plan to achieve our water reduction target30
of 40% by emphasizing water treatment andrecycling as well as reduced primary usage. While
our strategy is global, we work with different Amgen sites
particularly in water-stressed regions.
Amgen completed externally validated water studies at
each of our major manufacturing sites in 2021 to identify
additional reduction opportunities. We also established across-functional water sustainability team to share projects
and best practices globally.
By the end of 2021, Amgen had identified more than 90
potential water reduction projects. These are being reviewed
for viability and prioritization, including some key projects
involving large utility systems such as reverse osmosis skids
and cooling towers. In 2021, Amgen developed water
reduction pipeline proposals with the potential for highimpact at facilities in water-stressed regions.

As of September 30, 2021.
Developed by the U.S. Green Building Council, LEED is a set of rating systems
for the design, construction, operation, and maintenance of green buildings,
homes and neighborhoods.
28
Based on a 2019 baseline.
29
Carbon neutrality goal refers to Scope 1 and 2 emissions.
30 
Reductions take into account only verified reduction projections, do not take
into account changes associated with the contraction or expansion of theCompany and are measured against a 2019 baseline.
26

27 

Introduction

ENVIRONMENTAL SUSTAINABILIT Y
WASTEWe plan to reduce 75% of waste disposed31
through recycling and reuse of waste materials
sent to landfills or disposed via combustion or
incineration without energy recovery. In 2021, three Amgensites did not send any waste to landfills.
While our strategy prioritizes innovation and efficiency to
reduce waste before it’s generated, for 2021 Amgen Rhode
Island transferred the majority of the landfill waste it did
generate to a neighboring state for energy recovery. Thechange was made, in part, because the Rhode Island Central
Landfill, which provides disposal for 97% of Rhode Island
residents, is projected to reach its capacity in the next decade.

incineration is a better alternative“ Waste-to-energy
to landfills for waste disposal and actually
reduces the amount of greenhouse gas emissions
in the atmosphere.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Mask Recycling – A Silver Lining of the COVID Cloud
The emergence of COVID-19 in 2020 brought with it theneed for our employees to wear personal protective
equipment (PPE), including masks, and in some cases
gloves at Amgen facilities. However, while helping protect
the safety of employees and contractors at our sites, we
also wanted to mitigate unnecessary waste.
Beginning in July 2020, we partnered with a global leader
in recycling hard-to-recycle materials to help. Through ourpartnership, our employees can dispose of used PPE in onsite
collection boxes. Our third-party vendor then breaks down
the used PPE into its component fibers and plastics, which
can be used to create new products such as plastic lumber
for park benches. Through 2021 we recycled—and diverted
from landfills—approximately one metric ton of masks at
our corporate headquarters in Thousand Oaks, California.

A Healthy Amgen

Appendix

SUSTAINABILITY BY DESIGN
We are growing with the future in mind by integrating
sustainability into our expansion efforts. In 2021, we
upgraded our LEED design and construction standards
from Sliver to Gold certification for all new buildings andmajor renovations.This includes the design, construction,and operation of our planned new facilities in Ohio andNorth Carolina. LEED is the most widely used green
building rating system in the world.
We also initiated an internal carbon fee as part of ourinvestment lifecycle management (ILM) process, which
includes capital projects and building leases. Beginning in
2021, this process now requires project-specific sustainability
plans and assigns an internal price to carbon emissions,water intake, and waste generation. For example, projects
that increase carbon emissions above an establishedthreshold are charged an internal carbon fee to help ensurethat the impact to the environment is accounted for in ourdecision-making as we consider alternative options withlower environmental footprints.

”

JIM RAWLEY, Environmental Healthy & Safety
Manager at Amgen Rhode Island

Reductions take into account only verified reduction projections, do not take
into account changes associated with the contraction or expansion of theCompany and are measured against a 2019 baseline.

31 

4 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

ENVIRONMENTAL SUSTAINABILIT Y

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

We also started to phase out use of PVC in secondary
packaging, an accomplishment our manufacturing sites
in Ireland and the Netherlands were the first to achieve in
2021. Moreover, in addition to efforts to promote biodiversity,
we remain committed to using fully recyclable paperboard
from certified sustainable forests in the packaging of all
Amgen products and, where regulation allows, to shift toelectronic leaflets.
In 2021, the Australian Packaging Covenant Organisation
honored Amgen with its Healthcare and Scientific Award.
The award showcases Australian industry’s commitment tomeeting the nation’s 2025 packaging targets and buildinga regenerative, or circular, economy approach to packaging.
Among its efforts, Amgen is participating in the reusable
Cool Green Shipper collaboration with the logistics
company DHL and also examining recyclable and renewable
alternatives to PVC in packaging trays for several products
packaged in Australia.

SUSTAINABLE PACKAGING
Amgen is on a journey to reduce the environmental
impacts of its packaging through its Global Packaging
Sustainability program.
In 2021, we enhanced our Green Packaging Assessment
process, showing its impact on our carbon footprint. Moving
forward, we plan to conduct life-cycle assessments on
existing packaging to inform new, more sustainable designs
for Amgen products that reduce adverse impacts on thevariety of life in the world, or biodiversity.

4 9 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

FINDING NEW HOMES FOR SURPLUS ASSETS
To conserve financial resources and reduce environmental
impact, Amgen maintains a robust Surplus Asset Management(SAM) program, where staff can repurpose or donate
equipment for reuse. This includes items such as laboratory,
manufacturing, and facilities equipment; office furnitureand supplies; and carts, glassware, and spare parts. SAM also
auctions equipment and donates to nonprofit organizations,educational institutions, and programs like the Amgen
Biotech Experience (see page 39), an innovative scienceeducation program that empowers teachers to bringbiotechnology into their classrooms.

A Healthy Amgen

Appendix

In 2021, we diverted approximately 82 metrictons of materials from landfills through SAM.
For assets not able to be repurposed, SAM
responsibly recycled approximately 17 metrictons of material.
Since the program began in 2012, we diverted
approximately 1,950 metric tons of materials
from the landfill through SAM.
Of this amount, 123 metric tons has been
donated to educational programs andnonprofit organizations.
While the program is currently only in the United States,
we are exploring expansion to other Amgen sites in Europe.
University of Massachusetts Lowell was one SAM recipient in
2021, receiving donated pipettes and other lab equipment
for use in its Cell and Tissue Engineering teaching labs.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

ELECTRIC VEHICLE PILOT PROGRAM ADVANCESCARBON NEUTRALIT Y GOAL 32
Brent Meeks spends most of his workdays at Amgen behind
the wheel of a car. As a Senior Specialty Sales Representativein Northern California, he visits physicians as much as twohours away from his home across a large rural territory thatstretches from Yreka to Davis, California. When he received anemail asking for volunteers to join a new electric vehicle pilot
program for Amgen’s U.S. field fleet, the self-described “carand technology nerd” jumped at the chance to take part.

“I was excited to join the pilot program
because I know electric vehicles are thefuture,” said Meeks. “Along with thesustainability benefits, they’re fun to drive!”
Globally, Amgen’s field fleet represents around 15% of
the Company’s overall carbon footprint, making it the thirdlargest contributor of carbon emissions, behind Amgen’s
manufacturing facilities in Juncos, Puerto Rico, andThousand Oaks, Calif.
The goal of the pilot program is to capture lessons learnedin preparation for launching a minimum of 1,800 electricvehicles on the road globally by 2027.
32
33

Carbon neutrality goal refers to Scope 1 and 2 emissions.
Based on a 2019 baseline.

5 0 | E NV I RON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

“It will take global participation to help Amgen reach carbon
neutrality32 by 2027,” said Yanina Barrera, Ph.D., Principal
Engineer, Engineering Technical Authority, who leads
Amgen’s sustainability efforts to increase electrification33 of
the field fleet to at least 30%, “ and electrifying our fleet incountries that are ready is critical to making that happen.”
The pilot has not been without challenges, ranging from thelower mileage range of electric vehicles paired with limited
charging infrastructure availability in some territories, andthe lack of available vehicles due to supply chain issues.
Nevertheless, as of January 1, 2022, Barrera’s team has placedorders for 195 electric vehicles, which have been assigned
to field staff. Planning is also underway for deploymentof all-electric vehicles in other geographies, and we havelaunched the program in the Netherlands and South Korea.
To support the transition, Amgen is providing home charger
installation and hosting driver workshops to educate on
issues such as public charging stations and reimbursement
processes for electricity usage.
For Meeks, its an experience he has been glad to be part of.
“I look forward to driving the car -- It’s fun, it’s high tech, andit puts a smile on my face every time.”

Introduction

ENVIRONMENTAL SUSTAINABILIT Y
2021 PERFORMANCE DATA
We measure and report on our overall carbon emissions,energy, water use, and waste disposed. We include data
gathered from 16 manufacturing, R&D, and distribution
facilities located in North America, South America, Asia, andEurope, representing (based on square footage) approximately
88% of our operations. For the remaining 12% of square
footage, primarily administrative offices, we estimate energy
usage to calculate carbon emissions. We measure progress
toward our targets by quantifying results independent ofgrowth or contraction of our business. We do not include
facility or building closures or recently acquired facilities in
our target progress. Our 2021 environmental data haveundergone a reasonable assurance audit. Highlights of ourenvironmental performance are presented below; moredetailed data can be found here.

5 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

OTHER REPORTS

ENERGYThe CDP is an international nonprofit organization andreporting platform that helps companies and cities disclose
their environmental impacts. Since 2010, Amgen has reported
to the CDP and you can find our most recent CDP reports
for Climate Change and Water here. Our reports provide
additional details about Amgen’s governance, strategy,
risk management, metrics, and targets related to climatechange and water.

In 2021, we increased the amount of renewable energy in
our purchased electricity to 79% compared to 41% in 2020.
We purchased in-country renewable energy certificates tomake our facilities in Thousand Oaks, CA; West Greenwich,
RI; Louisville, KY; Cambridge, MA; Breda, Netherlands; andSingapore use 100% renewable electricity. This is in addition
to our GreenPower Purchase Plans with local utilities at ourfacility in Ireland and our two locations in Great Britain.

Over time, CDP’s disclosure platform for climate change has
evolved to contain over 25 questions (within its governance,risks and opportunities, strategy, targets and emissions
modules) that are aligned with the recommendations of the
Task Force on Climate-related Financial Disclosures, or TCFD;
this platform is now nearly in full alignment with the TCFD.
We continue to report to the CDP as completely as possible
and, in 2022, we are undertaking a TCFD-aligned scenario
analysis assessment to improve our understanding of thephysical and transitional effects of climate change as wellas to inform our future reporting. Additionally, while theCompany’s 2027 environmental sustainability targets do
not incorporate Scope 3 emissions, we continue exploring
approaches to better understand this area, including
identifying potential emissions reduction opportunities inour value chain.

2021 Energy Use by Source(1,000 GJ)

7

1,131

1,060

383
1

609

NuclearNatural Gas

Diesel

PropaneFossil Fuel

Renewables

Introduction

ENVIRONMENTAL SUSTAINABILIT Y
CARBON
Carbon emissions from onsite combustion of fuel andpurchased energy in 2021 decreased by 88,000 metric tons
(MT) from 2020. This represents a 36% reduction fromthe previous year and was primarily achieved through theincreased procurement of renewable electricity, as discussed
above, for our North American facilities.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

WATER

WASTE

Our total water usage in 2021 decreased by 117,000 cubic
meters (CM) from 2020. Water usage decreases are a result ofwater reclamation projects, irrigation control enhancements
and completion of equipment commissioning (which
temporarily increased water usage in 2020). Since 2007, wehave avoided the usage of 1 million CM annually through theimplementation of water innovation and efficiency projects.

Waste disposed decreased in 2021 primarily due to anincrease in the Amgen Rhode Island waste-to-energy
conversion at a nearby facility. The Amgen Rhode Island
manufacturing facilities now divert 80% of landfill waste
to the waste-to-energy facility.

Carbon Emissions From Onsite
Combustion of Fuel and Purchased Energy

Water Intake

Waste Generation(1,000 CM)(MT)(1,000 MT)

6

400

133

129

133

3500

977

3000

4

55

977

977

300

133

416

2500

249

243

8000

3,286
2,146

1500

183
1000

2000
200

2,355

884

12000

2,238

6,329

6,678

7,466

3,490

3,163

2,823

2007*

2019**

2020

2021

Waste
Disposed

Waste Recycled, Composted,
Incinerated With Energy
Recovery 2007-2019

6000
4000

155

3,542

6,604

1000

100

2000

2007*
CarbonEmissions

2019**

2020

Annual Carbon
Emissions Avoided
2007-2019

2021
Annual Carbon
Emissions Avoided
2020-Present* Amgen Sustainability program base year. ** 2027 Plan base year.
5 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

500

2007*
Water
Intake2019**
Annual Water
Intake Avoided
2007-2019

2020

2021
Annual Water
Intake Avoided
2020-Present

Reductions in
Waste Disposed
2020-Present

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

AppendixA H E A LT H Y A M G E N
We hold ourselves to high standards in our operations—working to ensure that
our actions and culture reflect Amgen’s values.

2021 Highlights

ZERO

class 1 or 2 product recalls*

800+

Amgen employees served as
cybersecurity ambassadors,
representing 34 countries andevery function within the Company

100%of employees trainedon the Code of Conduct*A Class 1 recall recall is defined by the U.S. Food and Drug Administration (FDA) as a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. A Class
2 recall is defined by the FDA as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

5 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

AppendixA H E A LT H Y A M G E N
Our business is built on an unwavering commitment to integrity and compliance, which is demonstrated byour staff members every day through their words, decisions and actions.
Our commitment to integrity and compliance requirespreserving our heritage of high ethical values and standards,
ensuring accountability for our actions, and putting thepatient first. Quite simply, it requires doing things right anddoing the right things.

AMBITION
We seek to strengthen andmaintain the trust of the
stakeholders we serve. This
is not only the right thing todo, but also essential for the
long-term health of Amgenand all we serve.

This approach is woven through all facets of our organization
by robust governance practices, global policies, performance
management systems, training, and ongoing monitoring andremediation. It is also built on a culture of transparency andengagement with stakeholders.
This section includes:

CORPORATE GOVERNANCE
BUSINESS ETHICSETHICAL RESEARCHPATIENT SAFET Y & PRODUCT QUALIT YCYBERSECURIT Y & DATA PRIVACYGOVERNMENT AFFAIRS & PUBLIC POLICY

5 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

CORPORATE GOVERNANCE
Effective corporate governance is criticalfor both our long-term performance andmaintaining stakeholder trust.
Amgen has a highly independent Board of Directors electedannually by a majority of our stockholders, with a leadindependent director with robust responsibilities. Only
independent Board members serve on key standing
committees. Key standing committees of our Board include
the Audit, Compensation and Management Development,
Corporate Responsibility and Compliance, and theGovernance and Nominating Committees.
Our Board of Directors is guided by our Amgen Board of
Directors Corporate Governance Principles that are amended
from time to time to incorporate certain current best practices
in corporate governance. Our Board operates in alignment
with two codes of business conduct—the Amgen Board of
Directors’ Code of Conduct that applies to our Board anda global Code of Conduct that applies to our Board, all our
staff, and others conducting business on our behalf. Annual
training on the global Code of Conduct is required andour Board participates in such training. Our Corporate
Governance Principles and codes of conduct may be foundon our website.

5 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Board of Director composition is an area of focus for the
Board. Reflecting our Board’s commitment to refreshment,
the Board has appointed seven new directors since 2015,
including women as well as those from underrepresented
communities, adding critical skills and experience to our
Board in furtherance of our strategic priorities.
Our Governance and Nominating Committee regularly
screens and recommends candidates for nomination by
the full Board and, among other things, considers feedback
received during the annual Board and committee evaluation
process, investor feedback, our qualification guidelines andskills matrix, director commitment levels (with consideration
given to public company leadership roles and outsidecommitments) and diversity.
The Governance and Nominating Committee and the Boardof Directors view diversity as a priority, consider diversity inits determinations, and seek representation across a range of
attributes. Diversity includes race, ethnicity, age, and genderand is also broadly construed to take into consideration manyother factors, including industry knowledge, operational
experience, scientific and academic expertise, geography, andpersonal background. In an effort to best support maintaining
and expanding the diversity of our Board, our Governanceand Nominating Committee actively seeks diverse candidates,
including women and minority candidates, as part of its
search for new directors.

A Healthy Amgen

Appendix

As part of its oversight of the Company, our Board of
Directors oversees an enterprise-wide approach to risk
management, which is designed to support the achievementof the Company’s objectives, including its strategic priorities
to improve long-term operational and financial performanceand deliver stockholder value. Our Board believes thata fundamental part of risk management is understanding
the risks that we face, adopting appropriate controls andmitigation activities for such risks, monitoring these risks,and responding to emerging developments for such risks.
For more information on our Board and our corporate
governance practices, please visit our website and our2022 Proxy Statement.

3

2

25%

FEMALE
DIRECTORS

917%
DIVERSE

DIRECTORSCORPORATEGOVERNANC

10GENDER
DIVERSITY

RACIAL/ETHNIC
DIVERSITY

Introduction

BUSINESS ETHICSCOVID-19 Response

Healthy People

Healthy Society

A Healthy Amgen

Appendix

Amgen staff are privileged to be part of a Company that develops and delivers medicines to treat
seriously ill patients. That privilege comes with important ethical and legal considerations. To deliveron our mission, we must conduct business ethically and with integrity, and also effectively comply
with the laws and regulations that govern our business and industry.

VALUE CREATION
We operate within a highly
regulated and increasingly
complex environment.
Our Worldwide Compliance and Business Ethics
organization is charged with navigating theserequirements and anticipating emerging issues.
We do this through our annual Global Risk
Assessment and by developing proactive plans to
mitigate the risk of unethical business practices.
We disclose policies that govern how we operate
and our efforts to help ensure enterprise-wide
compliance with them to further increase thetrust and support of our stakeholders.

5 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Healthy Planet

Together, the Amgen Values and Code of Conduct serve
as principles that guide the way we conduct business. The
Amgen Values define the day-to-day behavioral expectationsof every Amgen staff member around the world. The Codeof Conduct is our guide to doing the right thing. Including
demonstrating high ethical standards, good judgment, andaccountability for our actions.
Our Code of Conduct applies to every person who does
business on behalf of our Company worldwide—including
our Board, all employees and all levels of management, as
well as consultants, contract workers, and temporary workers(as applicable by law). We require all employees to take Codeof Conduct training annually; our Code is available in 24
languages to support global understanding.
Our staff and anyone external to the Company can reportsuspected misconduct or ask a question by phone or via
the Internet using Amgen’s Business Conduct Hotline. We
provide regular updates on the number and types of reports
received through the Business Conduct Hotline to the
Corporate Responsibility and Compliance Committee of our
Board of Directors. Amgen’s nonretaliation policy prohibits
any form of retaliation or intimidation against Amgen
employees for reporting a concern in good faith.

Introduction

BUSINESS ETHICS
Tone at the Top
Our leaders play a critical role in creating an ethical culture.
At Amgen, all managers are responsible for maintaining awork environment that encourages asking questions andreporting concerns regarding business conduct. All Amgenleaders (vice president and above, plus other select roles)
must participate in our annual Global Ethics and ComplianceDeclaration Program, which provides them with a framework
and resources to demonstrate their commitment to ethics
and compliance. Leaders are required to execute an ethics
and compliance engagement plan and sign a declaration
form confirming that they have executed against their planand have reported any potential noncompliance incidents
to Human Resources or the Business Conduct Hotline(including any violations of our Conflict of Interest policy).
Strengthening Our Safe-to-Speak-Up Culture
In 2020, we found through employee survey responses
that our employees wanted to better understand Amgen’s
Business Conduct Hotline. This led to efforts in 2021 tostrengthen Amgen’s speak-up culture and raise awareness ofAmgen’s report handling and investigative process, as wellas our nonretaliation policy. Our goal is for 100% of Amgen
employees to be aware of how to report concerns or ask
questions and feel comfortable doing so. During the first halfof 2021, we created and disseminated awareness materials
through multiple channels, including our leaders, to help set
the correct ethical “tone at the top.”
5 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Robust Anti-Bribery/Anti-Corruption
Compliance Program
We are committed to competing lawfully and ethically in themarketplaces across the geographies in which we operate.
We have a robust anti-bribery/anti-corruption program,which includes a global policy that states our expectationthat all employees “conduct all aspects of Amgen businesslawfully and with integrity.” All employees are trained on
this policy as part of our annual Code of Conduct training.
Tailored, function-centric training is also assigned to selectgroups such as Global Commercial Operations, Researchand Development, and Operations. In addition, we performperiodic risk assessments to support programmatic
improvement opportunities, as well as ongoing audit andmonitoring activities. Our anti-bribery/anti-corruption
program also extends to third parties and intermediaries
doing business on behalf of Amgen and includes periodic
auditing, training, and due diligence.
MORE INFORMATIONBusiness Ethics and Compliance
Staff Code of Conduct
Board of Directors Code of Conduct
Code of Ethics for CEO and Senior Financial Officers
Corporate Compliance Policies
Reporting a Concern at Amgen

A Healthy Amgen

Appendix

2021 PERFORMANCE DATA

83%

of Global Pulse Survey respondents
stated they are aware of the various ways
to seek guidance on ethical matters100%of employees trainedon the Code of Conduct

Making Compliance Easier Than Ever
In 2021, we made it easier for employees to be compliant
by streamlining and consolidating policies around theglobe and making information easier to find. In the
United States, this included the introduction of theAmgen BlueBook, which combines our U.S. Healthcare
Compliance requirements into one comprehensive
document to better enable employees to find thecompliance information they need to do their jobs in
an intuitive, flexible, and responsive way.
We also introduced several “just-in-time” microlearning
courses to employees based on their roles and daily
activities to increase engagement and knowledge retention.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

ETHICAL RESEARCH

Amgen aims to discover, develop, and deliver transformative medicines to address someof the leading causes of death and disability worldwide, working to meet the needs of as
many patients as possible.

VALUE CREATION

CLINICAL RESEARCH AND DEVELOPMENT

Conducting our R&D activities
in accordance with our internal
policies and external standards
helps to ensure the integrity ofand confidence in our trial
results and, ultimately, inmedicines approved for use.

At any given time, Amgen may conduct or is conducting
hundreds of clinical trials involving many thousands ofpatients. The rights, dignity, safety, and well-being of trial
participants are critical to the effective conduct of Amgen
clinical trials. To that end, our Global Code of Ethics governs
the design and conduct of Amgen-sponsored clinical trials.
Our high standards meet or exceed applicable local laws aswell as widely accepted international regulatory standards.

peer-reviewed journals within 18 months of trial completion. In
addition, we post technical summary results on the registries
in which the study was registered. We also register certain
Amgen-sponsored noninterventional studies on the EU PAS
Register before the start of data collection, including• post-authorization safety studies.
•o ther noninterventional studies when requested byour protocol governance committees, such as noninterventional studies planned for submission to
health authorities in a marketing application.

It also helps inspire confidence among potential
clinical trial participants, increasing the likelihoodof their enrollment in studies.

Amgen is committed to the timely registration of clinical
trials, communication of research results, and routine publication of Amgen-sponsored trials and observational studies.
We support the data-sharing initiatives and principles adopted by leading industry organizations, including the European
Federation of Pharmaceutical Industries and Associations(EFPIA) and the International Federation of Pharmaceutical
Manufacturers & Associations (IFPMA).

In 2021, in compliance with the EU Clinical Trial Regulation,
we began providing plain-language summaries of trial results
for all new interventional clinical trials that include sites inthe EU. Summaries are publicly available in every language
used during the clinical trial on the Amgen Trials webpage,
Trial Results Summaries portal, and, as applicable, on the EU
Clinical Trials Information System.

Amgen is committed to providing scientifically accurate,
truthful, nonmisleading, and well-balanced results to thescientific community – regardless of trial outcome or regulatory
approval. We aim to submit the results of the primary analysisof all completed Amgen-sponsored phase 2 and phase 3
studies (and some phase 1 studies) to medical congresses or

We continue to advance our work to improve diversity andrepresentation of racial and ethnic minority populations inclinical trial research at Amgen by advancing solutions andadvancing dialogue across the industry. We have developed
a framework to embed inclusive research principles across
our clinical trial lifecycle process. We are also working to

5 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

ETHICAL RESEARCH
develop relationships with community organizations,
HBCUs and Hispanic-serving institutions, government
officials, and healthcare providers and patients fromunderserved and underrepresented communities to raiseawareness of clinical trials and build trust. Moving forward,
we will continue to evolve how we capture, analyze, andreport demographic data for our clinical trials. To learn
more, visit page 21.

USE OF ANIMALS IN RESEARCH
We are committed to the ethical and responsible treatmentof animals required to be used in the discovery anddevelopment of our medicines. Amgen is a longtime
proponent of the principles of Reduction, Refinement, andReplacement (“the 3 Rs”) in the required use of animals in
research. Amgen is fully committed to the development anduse of scientifically validated alternative testing methods
that are acceptable to regulatory authorities and do notcompromise patient safety. We are engaged internally and incross-industry efforts aimed at developing and refining new
in-vitro testing and predictive systems that hold promise for
future reduction of animal usage. As part of these activities,
Amgen works directly with global regulatory authorities toincrease the recognition and acceptance of alternativemodels where such methods can be used appropriately.

5 9 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Amgen works to comply with all applicable global laws andregulations, including the gold standards of accrediting
bodies. We hold our external business partners, including
contract research organizations, academic institutions,and animal vendors, accountable to the same regulations,standards, and guidelines that govern our internal animalcare and use programs. We have a robust, proactive process
to monitor their compliance with our standards. In 2021, we
updated our Commitment to the Ethical Use of Animals in
Research policy statement to make our oversight process
more transparent.

A Healthy Amgen

Appendix

BIOBANKING OF HUMAN SAMPLES
Human samples play a vital role in Amgen’s research, including
helping to predict the safety and effectiveness of potential
new therapies and identify people most or least likely tobenefit from these therapies. Samples are collected, used,
stored, and disposed in accordance with the informed consent
of the patient and all applicable laws and regulations, including
those related to privacy and the use of human specimens
in research.

USE OF STEM CELLS
Amgen uses a wide variety of research tools and technologies
to help discover and develop new therapeutics, including
animal or adult cells in preclinical research to help unlock
new scientific insights, model complex diseases, screen newcompounds, and identify novel medicines. Amgen alsouses a small set of commercially available industry standard
immortalized cell lines acquired over several decades for
specific research-only purposes. Amgen has not, and does
not, perform or fund research in the area of humanembryonic or fetal stem cells. In 2021, we published a policy
position statement on our use of fetal stem cells, which isavailable here.

MORE INFORMATION
Global Code of Ethics for Clinical Trials
Clinical Trial Transparency, Data Sharing
and Disclosure Practices
Guidelines for Publications
Commitment to the Ethical Use of Animals
in Research
Position Statement on Stem Cell Research
Position Statement on Biobanking of
Human Samples

Introduction

PATIENT SAFET Y &PRODUCT QUALIT Y

VALUE CREATIONTo remain a leader in our sector,
we must continue to provide
healthcare professionals andpatients with confidence inour products and the information
they need to prescribe anduse them appropriately.
We must also maintain the trust of worldwide
regulatory authorities through our commitment
to product safety and quality.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Appendix

With more than four decades of experience in biotechnology and a record of reliably supplying
high-quality medicines to patients, Amgen is a worldwide leader in research, development, andmanufacturing of complex biologic therapies focused on the safety of patients and the safe andeffective use of our products.
PATIENT SAFETY
Patient safety is overseen by Amgen’s Global Patient Safety
organization, whose work begins at the earliest stage of the
drug development journey, when a new product development
team is formed. All potential new Amgen medicines undergo
years of preclinical and clinical testing to establish theirsafety and efficacy profiles. This includes appropriate dosing
levels and acceptable benefit-risk profiles. Once a productreceives marketing approval from health authorities, safety
data collection continues through multiple channels. This
includes additional clinical and post-marketing studies,
reports by patients and healthcare professionals, registries,and scientific literature.
Our Global Patient Safety organization includes Amgencolleagues in 46 countries. Amgen’s Global Patient Safety
team executes pharmacovigilance activities in collaboration
with our worldwide team members, including Local Safety
Officers (LSOs) who provide expertise and oversight regarding
regional and country-specific regulatory requirements.
Through our pharmacovigilance system, we capture,
document, and evaluate adverse events and other safety
reports regarding the use of our therapies. Data collected areprocessed and analyzed centrally by our pharmacovigilance

6 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

A Healthy Amgenteam, in compliance with global and local regulatory
requirements. Our Global Patient Safety team maintains
oversight of all pharmacovigilance-related activities andcollaborates with colleagues across Amgen to communicate
product information in a timely, transparent, and accurate
manner to patients, prescribers and regulatory agencies
around the globe.

Global Patient Safety, we see ourselves as the“ Invoiceof the patient, for every patient using Amgenproducts throughout that product’s lifecycle. ”
FATIMA BHAYAT,Vice President and Head of Global Patient SafetyIntroduction

PATIENT SAFET Y &PRODUCT QUALIT Y
All Amgen staff complete annual training on adverse eventsand product complaint reporting. Amgen staff who learnof potential adverse events, product complaints, and othersafety findings are required to report the information to ourGlobal Patient Safety team in accordance with our corporate
policies and Code of Conduct.
Investing in Technology to Increase Safety,
Efficiency, and Compliance
In recent years, there have been major changes in thepharmacovigilance regulatory landscape. At the same time,
our product portfolio and development pipeline havecontinued to expand, as has the number of countries inwhich we market our products. We continuously implement
improvements as appropriate to increase the efficiency ofour pharmacovigilance system, enhance the quality of ourdata, strengthen compliance with regulations, and help
promote patient safety. As part of our efforts, we continue
to enhance our use of technology to further automate
capabilities for adverse event and other safety reports
coming from Amgen’s U.S. Medical Information Call
Center and other companies that market our medicines
in different countries.
We are also using artificial intelligence to expedite andenhance our processes to produce higher-quality data
insights. With these insights, we use analytical tools to

6 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

conduct root cause analyses to better understand andproactively address product safety and quality concerns– with the objective to enhance patient experiences with
Amgen products.

PRODUCT QUALITY
We employ an enterprise-wide Quality Management System(QMS) composed of processes that work together to translate
customer, quality, and regulatory requirements into Amgenproducts to help ensure a favorable safety and effectivenessprofile through each stage of a product’s lifecycle. This
supports our ability to reliably supply high-quality medicines
to patients on time every time. The system includes numerous
quality checks and is based on a set of global Quality by
Design principles. It is built in accordance with more than150 country, regional, and international standards andregulations covering pharmaceuticals, medical devices, andcombination products including ISO 13485, current Good
Manufacturing Practices (cGMP), and ICH guidelines. We holdthe required clinical, commercial, manufacturing, wholesaleand distribution licenses, as well as necessary GxP certificatesissued by governing health and regulatory authorities.
We conduct investigations when deviations to our
specifications or quality standards occur. We determine theroot cause and implement corrective actions to ensure that
we maintain high levels of compliance and quality.
Amgen has a robust QMS training program for all of ouremployees and many third parties. All third parties providing
services or products manufactured to GxP standards are

A Healthy Amgen

Appendixrequired by regulation to have their own quality assurance
department and a formal training process. Our training
program is rigorously examined during internal and external
audits. New employees receive training on cGMP, otherregulatory requirements and emerging trends. Existing
employees receive this training on an annual basis.
We assess compliance with our QMS and global regulations
through audits conducted by our internal audit teams.
Our audit plans are risk-based and assess operations or
activities with a higher potential to affect product quality
and/or patient safety.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

PATIENT SAFET Y &PRODUCT QUALIT Y
SUPPLIER COMPLIANCE
External service providers, component suppliers, andcontract manufacturers play an increasingly importantpart in Amgen’s manufacturing strategy. Their operational
performance and compliance with applicable regulations
have direct impact on the quality of Amgen final drug
and combination products. Because of this, we audit theoperations of our suppliers to help ensure the products
they manufacture or services they provide meet Amgen’s
and regulators’ expectations for quality. We have formal
programs to continuously monitor the performance andprovide oversight and support for our suppliers.
MORE INFORMATION
Global Patient Safety
About Amgen Clinical Trials
Adverse Event and Product Complaint Reporting
Quality Assurance of Our Medicines

GUARDING AGAINST COUNTERFEIT MEDICINES
Amgen takes the issue of counterfeit drugs very seriously andapplies significant efforts to deter, detect, and disrupt criminal
counterfeiting of our medicines, including
Employing sophisticated technology to hamper theability of counterfeiters to create packaging that
resembles Amgen’s packaging.
In the United States, requiring wholesalers to buy only
directly from Amgen, and auditing compliance withthese purchasing practices.
Partnering with federal and state law enforcement
agencies to investigate and prosecute those involvedin product tampering and counterfeiting, facilitating
the arrest and conviction of counterfeiters.
In addition, Amgen uses industry-leading serialization andtraceability technologies where required to advance thesecurity of the supply chain and protect our products andpatients. Amgen products have distinctive security featuresthat allow us to confirm whether a product has been legitimately
produced following Amgen quality standards.
For more information, see our counterfeit drug statement.

6 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

CYBERSECURIT Y & DATA PRIVACYVALUE CREATION
Amgen relies on information
systems to operate its business,
including the collection andretention of personal data
entrusted to us by patients,
customers, employees,
and others.
Continued access to data allows Amgen todevelop and deliver products and solutions thatprovide value to patients worldwide and improvehealth outcomes. In addition, strong defenses
against cyber threats support the Company’sbusiness continuity and resilience.

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

The international standard for information security management developedby the International Organization for Standardization and the International
Electrotechnical Commission.

6 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Appendix

We have robust systems and processes in place to support the ethical use, management,
and protection of all information and data.
Our Chief Information Security Officer oversees ourenterprise-wide cybersecurity program, which follows
internationally recognized industry standards including
ISO/IEC34 27002. Amgen has multiple mechanisms in placedesigned to guard against cyber threats, including a global
team that gathers threat intelligence and conducts ongoing
monitoring. Our Global Privacy Compliance team maintains
policies and processes that guide how we collect, maintain,
and protect personal information based on the legal andregulatory requirements of the many regions where we dobusiness. Examples of the practices we follow to support
the integrity of our data protection processes include

	Monitoring technical and organizational measures
to safeguard the data through appropriate user
access management, secure file transfers, andconsent management.

	Collecting and using the minimum amount of
personal information necessary to achieve ourbusiness purposes.

We also host regular employee awareness events andcampaigns on topics such as ransomware, identity theft, andmobile security, and conduct internal phishing exercises.
New in 2021, to keep employees educated and engaged on
cybersecurity, we launched a series of virtual cyber escaperooms where teams compete to solve security challenges.

	Sharing personal information only with individuals
who have a legitimate need for it and will protect it.
	Maintaining appropriate administrative, technical,
and organizational security measures to protect
personal information.

34 

A Healthy Amgen

	Conducting vendor assessments to review third-party
applications and technologies that contain personaland sensitive information.

All Amgen employees receive annual security awareness andcompliance training that includes information on applicabledata security and privacy laws and regulations – including
the EU General Data Protection Regulation – and theappropriate handling of personal information in the
Company’s various markets. The global training programs
are available in 24 languages.

Amgen is also a member of the Health Information Sharing
and Analysis Center, a community of critical infrastructureowners and operators within the healthcare and publichealth sector focused on sharing timely, actionable, andrelevant information.
MORE INFORMATION
Protection of Personal Information Policy

Introduction
Introduction

COVID-19 Response

Healthy
HealthyPeople
PeopleHealthy
HealthySociety
Society

Healthy PlanetA
A Healthy
Healthy Amgen
Amgen

Appendix

INFORMATION SECURIT Y IS EVERYONE’S BUSINESSAt Amgen, protecting information is not
something that “someone else does” – itis a responsibility everyone shares.
“Increasingly sophisticated threats to our information anddata, including the personal information entrusted to us andthe records we maintain, is a matter of concern to us all,” said
Greg Barnes, Global Chief Information Security Officer atAmgen. “Information protection is a responsibility we all
share to achieve our collective mission of serving patients.”
To encourage employee engagement, the Company created
a community of security advocates through its Sentinels
Program. Now in its seventh year, the program has become
one of the largest of its kind in the private sector, with over800 Amgen employees serving as Chief Sentinels, representing
34 countries and every function within the Company.
Globally, 85% of all security incidents at large enterprises are
based on human error,35 such as inadvertently clicking on aphishing email or downloading malicious software. Amgen’s
Sentinels Program addresses these human-related risks
head-on with robust education and engagement programson our approach to prevent, defend, detect and respondto cyberthreats.

The program operates like a “Neighborhood Watch” for
information – a community of security advocates who,
working in partnership with Amgen’s Global Information
Protection (GIP) team, are the Company’s information
protection eyes and ears on the ground. They are alert andvigilant at a local level and, with GIP’s guidance, help theirlocal business area and team protect itself by keeping staff
informed about threats and empowered with tools andknowledge to stay secure.

“ A Sentinels’ role is simple and should bewhat we do every day as good corporate
citizens – be alert, respond to issues, andadvocate the use of information protection
best practices in everything we do.The
Sentinels Program is about putting our
information center stage and ensuringthat we all understand the important role
we all play in protecting it.

Alix Stahl, who is an Organizational Effectiveness Manager
at Amgen and has been a Chief Sentinel since 2014, says
there is an important “human factor to protecting Amgen’s
information.” Stahl helps train new hires on cybersecurity
and distributes awareness materials at Amgen headquarters,
where she is based.

”

ALIX STAHL,
Organizational Effectiveness Manager at Amgen

With training, any Amgen employee can become a Chief
Sentinel. All Sentinels receive ongoing training, which
involves innovative approaches such as cyber escaperooms and gamification where employees earn badges.

Verizon 2021 Data Breach & Incident Report (DBIR):
https://www.verizon.com/business/resources/reports/dbir/.

35 

6 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

GOVERNMENT AFFAIRS& PUBLIC POLICY

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

Appendix

Amgen operates in a highly regulated environment and decisions made by elected officials canhave a significant impact on our ability to serve patients.
Amgen’s Global Government Affairs and Policy (GGA&P) teamparticipates responsibly and constructively in the legislative
process. We work to communicate information to elected
officials and other policymakers in Washington, D.C., and in
U.S. state capitols around the country in support of public
policies that are consistent with our mission to serve patients—promoting access to new and existing medicines, fosteringscientific innovation, and protecting intellectual property.
Amgen supports candidates and organizations who work
to advance healthcare innovation and improve patient
access. We disclose all our political contributions on our
website. The Corporate Responsibility and Compliance
Committee of the Board of Directors oversees our approachto government affairs.
Amgen administers an employee-funded political action
committee (PAC) through which direct contributions are
made to federal and state candidates for elected office andrelated committees. The Amgen PAC supports candidates
from both parties. Decisions regarding who the PAC supports
are made without regard for the personal political preferencesof members of Amgen’s Board of Directors or PAC Board,
executives, or GGA&P staff. The Board of the Amgen PAC,
currently composed of 10 employees, has oversight of all
PAC activities. All PAC financial and compliance activities areaudited by a third-party firm.

6 5 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

A Healthy Amgen

Under certain circumstances, Amgen contributes to otherstate-level political committees. At this time, Amgen has
not made federal independent expenditures on behalfof candidates running for federal office under the 2010
Supreme Court decision in Citizens United.
In addition to the Company’s own political and legislative
activity, Amgen maintains memberships in trade associations
that report lobbying activity to the U.S. government. Amgensupports trade associations that champion scientific innovationand patient access to new and existing therapies.
Outside the United States, rules governing interactions with
policymakers vary by country. Amgen has implemented
internal policies regarding compliance with all applicablelaws and regulations in countries where relevant interactions
with policy makers occur, including the U.S. Foreign Corrupt
Practices Act.

MORE INFORMATION
Lobbying Disclosure Act reports
Lobbying disclosure by state
Political contributions and trade memberships

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXUNITED NATIONS GLOBAL COMMUNICATIONS ON PROGRESSThis report serves as Amgen’s Communication on Progress
for the United Nations Global Compact (UNGC). The statementfrom our CEO and Chairman at the beginning of the report
reaffirms our commitment to the principles of the UNGC,
and much of the content throughout this report highlights
progress in the four key areas of the UNGC: Environment,
Labor, Human Rights, and Anti-Corruption. Over the past 12
months, we have achieved progress in all four areas – a few
highlights follow.

HUMAN RIGHTS•	The Amgen Foundation committed $3 million in grants to
racial and social justice initiatives, economic empowerment,
and equal opportunity in education.
•	Amgen engaged with underserved and underrepresented
communities through a series of community health equity
advisory boards to help better meet their needs and build
long-term, sustainable relationships.
•	The Amgen Foundation promoted science education forunderserved students throughout the world throughinnovative virtual initiatives with Khan Academy and Harvard
University through LabXchange; these efforts reached over
27 million students and educators globally in 2021.
•	Continued to monitor our suppliers’ compliance with our
Supplier Code of Conduct and internationally recognizedhuman rights standards.

6 6 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

LABOR RIGHTS• In support of our OneTen pledge,36 we announced investments
in two new sites—located in North Carolina and Ohio—that
are expected to create more than 750 jobs drawing from adiverse field of talent.
•	Ninety-eight percent of staff worldwide completed
Managing Unconscious Bias training.
•	Increased membership in our 11 Employee Resource
Groups by 41 percent—membership now exceeds 11,000
employees in 60 global chapters.
•	Launched a mentoring program designed specificallyto help connect high-performing women of color withsenior leadership and provide opportunities for advocacy
and sponsorship.
•	Continued to monitor our suppliers’ compliance with our
Supplier Code of Conduct and internationally recognizedhuman rights standards including those that seek toprevent forced and child labor, support fair pay based on
applicable wage laws, and allow for freedom of association.

ENVIRONMENT•	Increased our total sourcing of renewable electricity to 79%
compared to 41% in 2020.
•	For the first time, we linked our executive pay to environmental
sustainability with the addition of an ESG goal in Amgen’s
annual incentive compensation plan.
•	Initiated environmental sustainability impact assessments
for all capital funding requests as part of Amgen’s capitalfunding program.

•	Updated Amgen’s sustainability design standard target for
the LEED certification.

ANTI-CORRUPTION•	Redesigned our U.S. Healthcare Compliance training
and standardized our global processes and compliancerequirements for international staff when interacting withmembers of the healthcare community.
•	Launched an initiative to strengthen Amgen’s speak-up
culture and raise awareness of Amgen’s report handlingand investigative process, as well as our nonretaliation policy.
•	Introduced the Amgen BlueBook, which combines our
U.S. Healthcare Compliance requirements into one
comprehensive document and enables staff to find thecompliance information they need to do their jobs in an
intuitive, flexible, and responsive way.
In addition to this report, Amgen provides extensive
reporting on policies and progress aligned with the UNGC
on our website. Below is a summary table providing dataaligned with the major categories of UNGC principles.

36

 e are a founding member of OneTen, a coalition of many of the world’sWlargest, best-known companies that aims collectively to hire 1 million Black
Americans (with a specific focus on Black Americans without four-year college
degrees) into well-paying, family-sustaining jobs over the next 10 years.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXCOMPANY PERFORMANCE DATA
Type

Unit

2017

2018

2019

2020

2021

DATA NOTES

Total Revenue$ Millions$22,849$23,747$23,362$25,424$25,979$ Millions$21,795$22,533$22,204$24,240$24,297i)	Please see Responsibility/Environment on
www.amgen.com for an Independent Verification
Statement forthis data. Amgen has included datafrom 17 facilities covering energy and carbon, water
and waste. The facilities represent approximately
88 percent of Amgen’s worldwide facility space
based on total square feet. Included facilities arein Thousand Oaks, California, U.S.; West Greenwich,
Rhode Island, U.S.; Juncos, Puerto Rico, U.S.; Louisville,
Kentucky, U.S.; South San Francisco, California, U.S.;
Cambridge and Woburn, Massachusetts, U.S.; Burnaby,
Canada; Breda, Netherlands; Dun Laoghaire, Ireland;
Uxbridge and Cambridge, United Kingdom; Sao
Paulo, Brazil; Yenibosna and Sekerpinar, Turkey;
Tuas, Singapore; and Shanghai, China. This includes
leased buildings where we have operational control
over building infrastructure, including utilities.

Product Sales
R&D Expenses$ Millions$3,562$3,737$4,116$4,207$4,819Total Energy (i)1,000 GJ

3,709

3,284

3,094

3,286

3,193

Total Carbon From Energy (i)1,000 MT CO Eq

278

263

249

243

155

Total Water Withdrawal (i)2,000 CM

2,320

2,093

2,146

2,355

2,238

2

Total Routine Waste (i)

MT

9,856

9,642

9,818

9,841

10,289Environmental Notices of Violation (NOVs) (ii)

1 NOV

1

3

2

1

3

Recordable Incident Rate

Injuries per 100 workers

0.36

0.42

0.31

0.31

0.19

Staff Lost Day Case Rate

Injuries per 100 workers

0.12

0.14

0.12

0.08

0.09

Staff Fatalities

People

1

0

0

1

0

Motor Vehicle Safety

Collisions per million miles

NA

NA

4.40

3.38

3.09

Amgen Employees*

People20,80021,50023,40024,30024,200% of Women in Total Workforce**

People

51

52

52

52

52

% of Women Management Level (iii)**

People

44

45

46

47

49

% of Women Executive Level (iv)**

People

37

36

39

42

44

% of Ethnic Minority in Workforce (U.S.)

People

45

45

47

48

51

% of Ethnic Minority Management Levels (U.S.) (iii)

People

39

39

41

42

44

% of Ethnic Minority Executive Level (U.S.) (iv)

People

24

25

27

30

32

Value of Medicines provided at no cost in low- and middle-income countries through Direct Relief (v)$ Millions

$0

$69+

$0

$73+

$5

Value of medicines provided at no cost to low-income patients in the United States through the$ Billions
Amgen Safety Net Foundation (v)

$0.9+

$1.2+

$1.4+

$1.5+

$2.2+

6 7 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21ii)	Environmental notices of violation (NOVs) reported
that resulted from agency inspections.
iiii)	Management: Senior managers and directors.
iv)	Executive level: Executive directors and above.
v)	Value calculated at wholesale acquisition cost.

*As reported in Amgen’s Form 10-K for the fiscal years
ended December 31, 2017 through 2021.
** D ata based on total headcount as reported in our Form
10-K for the year ended December 31, 2021, modified
to reflect active employee headcount which, among
other things, excludes co-ops and interns. Also excludes
Gensenta Pharmaceuticals and deCode Genetics.

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXSASB INDEXThis ESG Report is part of Amgen’s overall commitment to providing robust reporting on our ESG performance. We have also reported information in our Annual Report and 10-K, as well as our
Proxy Statement, which may be useful to our investor’s understanding of our activities that support our ESG efforts. As noted previously, this ESG Report was prepared in alignment with the
Biopharma Sustainability Roundtable Investor ESG Communications Guidance, which considers key elements and principles of the Sustainability Accounting Standards Board (SASB) standard
for the Biotechnology industry.
In the table below we have indicated where Amgen reports on metrics that are included in the SASB standard, including sections of this Report, our website, our proxy statement and ourperiodic filings with the Securities and Exchange Commission (SEC). Our ESG reporting continues to evolve and expand – as a result, where we have indicated that we do not report on ametric at this time, we will continue to evaluate our ability to report on that metric in the future.

SASB TOPIC

Safety of Clinical
Trial Participants

ACCOUNTING METRICUNIT OFMEASURECODE

REPORTING

Discussion, by world region, management process for
ensuring quality and patient safety during clinical trials

n/a

HC-BP-210.a.1

Pertinent reporting can be found in the Product Quality
and Patient Safety section of this Report; the Global Codeof Ethics for Clinical Trials, Quality and Global Patient Safetysections of our website; and the Business and Risk Factors
section in Part I of the 10-K.

Number of FDA Sponsor Inspections related to clinical trial
management and pharmacovigilance that resulted in: (1)Voluntary Action Indicated (VAI) and (2) Official Action
Indicated (OAI)

Number

HC-BP-210.a.2

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Total amount of monetary losses as a result oflegal proceedings associated with clinical trials
in developing countries

Reporting currency

HC-BP-210.a.3

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

6 8 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXSASB TOPICACCOUNTING METRICUNIT OFMEASURE

CODE

Description of actions and initiatives to promote accessto healthcare products for priority diseases and in priority
countries as defined by the Access to Medicine Index

n/a

HC-BP-240a.1

See the Access to Medicines section of this Report, as wellas Access to Medicines Initiatives Outside the US section of
our website and the Improving Patient Access to Medicines
section of our 2022 Proxy Statement (within the Social
Responsibility subsection of the heading “Our Approach
to Environmental Sustainability, Social Responsibility, andHuman Capital Management”).

List of products on the WHO List of Prequalified Medicinal
Products as part of its Prequalification of Medicines
Programme (PQP)n/a

HC-BP-240a.2

None to disclose as of December 2021.

Number of settlements of Abbreviated New Drug
Application (ANDA) litigation that involved payments
and/or provisions to delay bringing an authorized
generic product to market for a defined time period

Number

HC-BP-240b.1

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Percentage change in: (1) average list price and(2) average net price across U.S. product portfolio
compared to previous year

Percentage (%)

HC-BP-240b.2

Pertinent reporting can be found in the Our Approach to
Pricing, Access and Affordability and Amgen’s Approach
to Responsible Pricing sections of our website; theManagement, Discussion and Analysis and Risk Factors
sections of the 10-K and quarterly 10-Qs; and the Approachto Pricing Our Products section of the 2022 Proxy Statement(within the Compensation Discussion and Analysis subsection).

Access to
Medicines

Affordability
and Pricing

REPORTING

6 9 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXSASB TOPIC

Drug Safety

ACCOUNTING METRICUNIT OFMEASURECODE

REPORTING

Percentage change in: (1) list price and (2) net price of
product with largest increase compared to previous year

Percentage (%)

HC-BP-240b.3

Pertinent reporting can be found in the Our Approach to
Pricing, Access and Affordability and Amgen’s Approach
to Responsible Pricing sections of our website; theManagement, Discussion and Analysis and Risk Factors
sections of the 10-K and 10-Qs; and the Approach to Pricing
Our Products section of the 2022 Proxy Statement (within
the Compensation Discussion and Analysis subsection).

List of products listed in the Food and Drug Administration’s(FDA) MedWatch Safety Alerts for Human Medical
Products databasen/a

HC-BP-250a.1

See FDA MedWatch database.

Number of fatalities associated with products asreported in the FDA Adverse Event Reporting System

Number

HC-BP-250a.2

See FDA Adverse Event Reporting System.

Number of recalls issued, total units recalled

Number

HC-BP-250a.3

See the 2021 Highlights in the “A Healthy Amgen” sectionof this Report; further, Amgen discloses material legal andregulatory issues in its annual 10-K and quarterly 10-Qs.

Total amount of product accepted for take-back, reuse,or disposal

Metric tons (t)HC-BP-250a.4

Data on product accepted through take-back can be foundin the Product Sustainability section of our website (seethe Product Packaging and Lifecycle section); in addition
we provide information about the California Safe Needle
Collection and Disposal Plan.

7 0 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXSASB TOPICCounterfeit Drugs

Ethical Marketing

ACCOUNTING METRICUNIT OFMEASURECODE

REPORTING

Number of FDA enforcement actions taken in response toviolations of current Good Manufacturing Practices (cGMP),
by typeNumber

HC-BP-250a.5

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Description of methods and technologies used to maintaintraceability of products throughout the supply chain andprevent counterfeiting

n/a

HC-BP-260a.1

Pertinent reporting can be found in the Counterfeit Drug
Statement on our website.

Discussion of process for alerting customers and business
partners of potential or known risks associated withcounterfeit products

n/a

HC-BP-260a.2

Pertinent reporting can be found in the Counterfeit Drug
Statement on our website.

Number of actions that led to raids, seizure,arrests, and/or filing of criminal charges related
to counterfeit products

Number

HC-BP-260a.3

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Total amount of monetary losses as a result of legal
proceedings associated with false marketing claims

Reporting currency

HC-BP-270a.1

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Description of code of ethics governing promotion ofoff-label use of products

n/a

HC-BP-270a.2

Our policy on Communications with Members of the
Healthcare Community and the Amgen Code of Conductprohibit off-label promotion and staff members are trainedon these requirements annually as described on the Staff
Code Conduct section of our website.

7 1 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXSASB TOPIC

Employee
Recruitment,
Development
and Retention

Supply Chain
Management

Business Ethics

ACCOUNTING METRICUNIT OFMEASURECODE

REPORTING

Discussion of talent recruitment and retention efforts forscientists and research and development personnel

n/a

HC-BP-330a.1

Pertinent reporting can be found on our Careers site, which
describes our approach to talent recruitment and retention;
also see the Human Capital Resources section (pages 22-24)
of our 10-K; and the Human Capital Management section of
our 2022 Proxy Statement (pages 34-35).

(1) Voluntary and (2) involuntary turnover rate for:(a) executives/senior managers, (b) mid-level managers,(c) professionals, and (d) all others

Rate

HC-BP-330a.2

Qualitative information about our staff turnover can befound in the Human Capital Resources section of 10-K for theyear ended December 31, 2021 and in the Chairman and CEO
Letter to Shareholders.

Percentage of (1) entity’s facilities and (2) Tier I suppliers’
facilities participating in the Rx-360 International
Pharmaceutical Supply Chain Consortium audit program
or equivalent third-party audit programs for integrity ofsupply chain and ingredients

Percentage (%)

HC-BP-430a.1

Amgen applies the requirements of its Quality Management
System as described in the Quality section of our website.

Total amount of monetary losses as a result of legal
proceedings associated with corruption and bribery

Reporting Currency

HC-BP-510a.1

Amgen discloses material legal and regulatory issues in its
annual 10-K and quarterly 10-Qs.

Description of code of ethics governing interactions withhealthcare professionals

n/a

HC-BP-510a.2

See the Interactions with Healthcare Providers section of our
website; our policy on Communications with Members ofthe Healthcare Community; and the Amgen Code of Conduct.
Staff members are trained on these requirements annually as
described on the Staff Code Conduct section of our website.

7 2 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

COVID-19 Response

Healthy People

Healthy Society

Healthy Planet

A Healthy Amgen

Appendix

APPENDIXACTIVIT Y METRICUNIT OFMEASURECODE

REPORTING

Number of patients treated

Number

HC-BP-000.A

Amgen regularly reports market segment share as part of its earnings
calls and in its earnings releases published through Business Wire andfurnished on Form 8-K.

Number of drugs (1) in portfolio and (2) in research and development(phases 1-3)

Number

HC-BP-000.B

Pertinent reporting can be found in the Products and Pipeline sections on
our website (generally updated quarterly) and the Business section of Part
I of our 10-K.

The inclusion of information contained in this disclosure should not be construed as a characterization regarding the materiality or financial impact of that information. Please also see our filed
Form 10-K, and other publicly filed documents available at https://investors.amgen.com/financials/sec-filings.
This report contains information about Amgen and may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements, other thanstatements of historical facts, may be forward-looking statements. Amgen cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which changeover time. Forward-looking statements speak only as of the date they are made, and Amgen assumes no duty to and does not undertake to update forward-looking statements. Actual results
could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. Factors that can cause results to differ, as wellas additional factors that can affect forward-looking statements, are discussed in Amgen’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, accessible on the SEC’s website atwww.sec.gov and on Amgen’s investor website at https://investors.amgen.com and https://investors.amgen.com/financials/sec-filings.

7 3 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

Introduction

APPENDIXFORWARD-LOOKING STATEMENTS
This report contains forward-looking statements that are basedon the current expectations and beliefs of Amgen. All statements,
other than statements of historical fact, are statements that could
be deemed forward-looking statements, including any statementson the outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd.,
Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic
antibodies against COVID-19), the performance of Otezla® (apremilast)(including anticipated Otezla sales growth and the timing of non-GAAPEPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the
Teneobio, Inc. acquisition, as well as estimates of revenues, operating
margins, capital expenditures, cash, other financial metrics, expected
legal, arbitration, political, regulatory or clinical results or practices,
customer and prescriber patterns or practices, reimbursement
activities and outcomes, effects of pandemics or other widespread
health problems such as the ongoing COVID-19 pandemic on ourbusiness, and other such estimates and results. Forward-looking
statements involve significant risks and uncertainties, including those
discussed below and more fully described in the Securities andExchange Commission reports filed by Amgen, including our mostrecent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unlessotherwise noted, Amgen is providing this information as of the dateof this report and does not undertake any obligation to update any
forward-looking statements contained in this document as a resultof new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Our results may beaffected by our ability to successfully market both new and existingproducts domestically and internationally, clinical and regulatory
developments involving current and future products, sales growth
7 4 | E N V IRON M E N TA L , SOC IAL & GOVERNANC E REPORT 2 0 21

COVID-19 Response

Healthy People

Healthy Society

Healthy Planetof recently launched products, competition from other products
including biosimilars, difficulties or delays in manufacturing our
products and global economic conditions. In addition, sales ofour products are affected by pricing pressure, political and public
scrutiny and reimbursement policies imposed by third-party payers,
including governments, private insurance plans and managed careproviders and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward
managed care and healthcare cost containment. Furthermore, ourresearch, testing, pricing, marketing and other operations are subject
to extensive regulation by domestic and foreign government regulatory
authorities. We or others could identify safety, side effects or
manufacturing problems with our products, including our devices,
after they are on the market. Our business may be impacted bygovernment investigations, litigation and product liability claims. In
addition, our business may be impacted by the adoption of new tax
legislation or exposure to additional tax liabilities. If we fail to meetthe compliance obligations in the corporate integrity agreement
between us and the U.S. government, we could become subject
to significant sanctions. Further, while we routinely obtain patents
for our products and technology, the protection offered by ourpatents and patent applications may be challenged, invalidated or
circumvented by our competitors, or we may fail to prevail in present
and future intellectual property litigation. We perform a substantial
amount of our commercial manufacturing activities at a few key
facilities, including in Puerto Rico, and also depend on third parties
for a portion of our manufacturing activities, and limits on supply
may constrain sales of certain of our current products and productcandidate development. An outbreak of disease or similar publichealth threat, such as COVID-19, and the public and governmental
effort to mitigate against the spread of such disease, could havea significant adverse effect on the supply of materials for our
manufacturing activities, the distribution of our products, thecommercialization of our product candidates, and our clinical
trial operations, and any such events may have a material adverse
effect on our product development, product sales, business andresults of operations. We rely on collaborations with third parties
for the development of some of our product candidates and for thecommercialization and sales of some of our commercial products.
In addition, we compete with other companies with respect to many of

A Healthy Amgen

Appendix

our marketed products as well as for the discovery and development of
new products. Discovery or identification of new product candidates
or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular productcandidate or development of a new indication for an existing productwill be successful and become a commercial product. Further, some
raw materials, medical devices and component parts for our products
are supplied by sole third-party suppliers. Certain of our distributors,
customers and payers have substantial purchasing leverage intheir dealings with us. The discovery of significant problems witha product similar to one of our products that implicate an entire
class of products could have a material adverse effect on sales of
the affected products and on our business and results of operations.
Our efforts to collaborate with or acquire other companies, products
or technology, and to integrate the operations of companies or to
support the products or technology we have acquired, may not be
successful. A breakdown, cyberattack or information security breach
could compromise the confidentiality, integrity and availability of
our systems and our data. Our stock price is volatile and may beaffected by a number of events. Our business and operations may be
negatively affected by the failure, or perceived failure, of achieving
our environmental, social and governance objectives. The effects ofglobal climate change and related natural disasters could negatively
affect our business and operations. Global economic conditions
may magnify certain risks that affect our business. Our businessperformance could affect or limit the ability of our Board of Directors
to declare a dividend or our ability to pay a dividend or repurchaseour common stock. We may not be able to access the capital andcredit markets on terms that are favorable to us, or at all.

Reference to our website is not intended to function
as a hyperlink, and the information contained on our
website is not intended to be part of this report.